var title_f15_53_16208="Pericardial melioidosis";
var content_f15_53_16208=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomography of pericardial melioidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 367px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Melioidosis involving the pericardium visible by CT scan.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bart Currie, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_53_16208=[""].join("\n");
var outline_f15_53_16208=null;
var title_f15_53_16209="Influenza virus vaccine (inactivated): Patient drug information";
var content_f15_53_16209=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Influenza virus vaccine (inactivated): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=see_link\">",
"     see \"Influenza virus vaccine (inactivated): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/21/20824?source=see_link\">",
"     see \"Influenza virus vaccine (inactivated): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9560252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Afluria&reg;;",
"     </li>",
"     <li>",
"      Fluarix&reg;;",
"     </li>",
"     <li>",
"      Flucelvax&reg;;",
"     </li>",
"     <li>",
"      FluLaval&reg;;",
"     </li>",
"     <li>",
"      Fluvirin&reg;;",
"     </li>",
"     <li>",
"      Fluzone&reg;;",
"     </li>",
"     <li>",
"      Fluzone&reg; High-Dose;",
"     </li>",
"     <li>",
"      Fluzone&reg; Intradermal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9560327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Agriflu&trade;;",
"     </li>",
"     <li>",
"      Fluad&trade;;",
"     </li>",
"     <li>",
"      Fluviral&reg;;",
"     </li>",
"     <li>",
"      Influvac&reg;;",
"     </li>",
"     <li>",
"      Intanza&reg;;",
"     </li>",
"     <li>",
"      Vaxigrip&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt adi-os drugH1Div\" id=\"F10031429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     CDC Information",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaccine Information Statements (VIS) are made by the staff of the Centers for Disease Control and Prevention (CDC). Each VIS gives information to properly inform the adult receiving the vaccine or, in the case of a minor, the child's parent or legal representative about the risks and benefits of each vaccine. Before a doctor vaccinates a child or an adult, the provider is required by the National Childhood Vaccine Injury Act to give a copy of the VIS. You can also get foreign language versions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <a href=\"file://www.immunize.org/vis/vis_flu_inactive.asp\" target=\"_blank\">",
"        Vaccine Information Statements (VIS)",
"       </a>",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11948 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3548BCC041-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_53_16209=[""].join("\n");
var outline_f15_53_16209=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560252\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9560327\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10031429\">",
"      CDC Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/61/985?source=related_link\">",
"      Influenza virus vaccine (inactivated): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/21/20824?source=related_link\">",
"      Influenza virus vaccine (inactivated): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_53_16210="Ultrasound normal fetal brain transcerebellar view";
var content_f15_53_16210=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Transcerebellar plane",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 423px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_53_16210=[""].join("\n");
var outline_f15_53_16210=null;
var title_f15_53_16211="Cortisol metabolism in chronic kidney disease";
var content_f15_53_16211=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cortisol metabolism in chronic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/53/16211/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/53/16211/contributors\">",
"     Biff F Palmer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/53/16211/contributors\">",
"     William L Henrich, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/53/16211/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/53/16211/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/53/16211/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/53/16211/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/53/16211/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of the hypothalamic-pituitary-adrenocortical axis in patients with chronic kidney disease has produced considerable controversy. As a consequence, the diagnosis of abnormal glucocorticoid metabolism can be challenging in this patient population.",
"   </p>",
"   <p>",
"    The kidney normally contributes to the excretion of cortisol and its water soluble metabolites. As a result, the serum half-life of cortisol becomes prolonged in advanced renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16211/abstract/1\">",
"     1",
"    </a>",
"    ]. Both normal and elevated levels of serum cortisol have been reported in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16211/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Methodological problems may in part account for the conflicting results. As an example, compounds (including metabolites of cortisol) accumulate in renal disease that can interfere with the accurate measurement of cortisol by several commercially available assays [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16211/abstract/2\">",
"     2",
"    </a>",
"    ]. Cortisol binding to corticosteroid-binding globulin remains normal, while binding to albumin is decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16211/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TESTS OF ADRENAL AND PITUITARY FUNCTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     ACTH, CRH, and metyrapone stimulation tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tests designed to assess the secretory capacity of the adrenal gland are typically normal. Thus, the diurnal variation in cortisol release is well preserved and circulating cortisol levels increase appropriately after an infusion of ACTH [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16211/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Cortisol levels also increase after the administration of corticotropin-releasing hormone (CRH); the expected rise in ACTH secretion is blunted in this setting, a response similar to that observed with chronic stress [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16211/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. For reasons that are unclear, the ACTH response to CRH is improved by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16211/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stimulation of ACTH and cortisol secretion following insulin-induced hypoglycemia or the infusion of CRH is impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16211/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. ACTH and 11-deoxycortisol responses are also blunted following the standard",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    test dose (30",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16211/abstract/9\">",
"     9",
"    </a>",
"    ]. This defect may be due to adrenal resistance to the blocking action of metyrapone in renal failure, since the response can be normalized by the administration of higher doses.",
"   </p>",
"   <p>",
"    Interpretation of these abnormalities may be complicated by the effect of hemodialysis on the plasma concentrations of CRH, ACTH, and cortisol. CRH levels fall during hemodialysis due to clearance across the dialysis membrane; despite this change, ACTH and cortisol levels increase in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16211/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dexamethasone suppression tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adrenal suppression tests, in comparison, have yielded conflicting results. In three different studies, low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (1 mg given the night before the measurement) produced normal suppression of the serum cortisol concentration, no suppression of cortisol or ACTH, and little or no suppression, but normal suppression of cortisol and ACTH following high-dose (3 mg) dexamethasone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16211/abstract/4,5,10\">",
"     4,5,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that the frequent ineffectiveness of low-dose oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    may at least in part be secondary to decreased drug absorption or altered metabolism in patients with renal failure (see below). Low serum levels of dexamethasone have been noted in those patients who fail to suppress morning serum cortisol levels after administration of 1 mg of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16211/abstract/10\">",
"     10",
"    </a>",
"    ]. However, the administration of higher oral doses (2 to 8 mg) or intravenous dexamethasone failed in one study to normally suppress the serum cortisol concentration despite adequate serum levels of dexamethasone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16211/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cortisol as a marker for treatment outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study of patients on maintenance hemodialysis found that an elevated predialysis serum cortisol concentration was predictive of increased morbidity, as defined by the need for hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16211/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, patients with a serum cortisol level above 22",
"    <span class=\"nowrap\">",
"     &micro;g/mL",
"    </span>",
"    <span class=\"nowrap\">",
"     (mg/L)",
"    </span>",
"    were more likely to have signs of malnutrition such as hypoalbuminemia and decreased triceps skin-fold thickness. It is unclear, however, if the high cortisol levels were markers of comorbid illness or were directly responsible for the catabolic state.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS OF EXOGENOUS STEROIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacokinetics of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    are altered in patients with chronic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16211/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is reduced plasma protein binding and increased clearance of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      There is reduced plasma protein binding but decreased clearance of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      . The fall in clearance may explain the apparently higher incidence of steroid-induced side effects when prednisolone is used in renal failure.",
"     </li>",
"     <li>",
"      The pharmacokinetics of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      are unaltered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the aggregate, there does not appear to be an overt abnormality in the function of the hypophyseal-pituitary-adrenal axis intrinsic to patients with chronic kidney disease. Nevertheless, findings such as spurious overestimation of plasma cortisol, altered cortisol binding to protein, decreased gastrointestinal absorption of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , and abnormal adrenal responses to dexamethasone make the diagnosis of Cushing's disease exceedingly difficult in this setting. One major difference between chronic kidney disease and Cushing's disease is that the circadian rhythm of cortisol secretion is preserved in the former and lost in the latter. It is not known if subtle abnormalities in glucocorticoid metabolism contribute to some of the findings of the uremic syndrome, such as insulin resistance and negative nitrogen balance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/43/18102?source=see_link\">",
"     \"Carbohydrate and insulin metabolism in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16211/abstract/1\">",
"      Bacon GE, Kenny FM, Murdaugh HV, Richards C. Prolonged serum half-life of cortisol in renal failure. Johns Hopkins Med J 1973; 132:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16211/abstract/2\">",
"      Nolan GE, Smith JB, Chavre VJ, Jubiz W. Spurious overestimation of plasma cortisol in patients with chronic renal failure. J Clin Endocrinol Metab 1981; 52:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16211/abstract/3\">",
"      Rosman PM, Benn R, Kay M, Wallace EZ. Cortisol binding in uremic plasma. II. Decreased cortisol binding to albumin. Nephron 1984; 37:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16211/abstract/4\">",
"      Barbour GL, Sevier BR. Letter: Adrenal responsiveness in chronic hemodialysis. N Engl J Med 1974; 290:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16211/abstract/5\">",
"      McDonald WJ, Golper TA, Mass RD, et al. Adrenocorticotropin-cortisol axis abnormalities in hemodialysis patients. J Clin Endocrinol Metab 1979; 48:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16211/abstract/6\">",
"      Siamopoulos KC, Dardamanis M, Kyriaki D, et al. Pituitary adrenal responsiveness to corticotropin-releasing hormone in chronic uremic patients. Perit Dial Int 1990; 10:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16211/abstract/7\">",
"      Siamopoulos KC, Eleftheriades EG, Pappas M, et al. Ovine corticotropin-releasing hormone stimulation test in patients with chronic renal failure: pharmacokinetic properties, and plasma adrenocorticotropic hormone and serum cortisol responses. Horm Res 1988; 30:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16211/abstract/8\">",
"      Watschinger B, Watzinger U, Templ H, et al. Effect of recombinant human erythropoietin on anterior pituitary function in patients on chronic hemodialysis. Horm Res 1991; 36:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16211/abstract/9\">",
"      Ramirez, G. Abnormalities in the hypothalamic-hypophyseal axes in patients with chronic renal failure. Semin Dial 1994; 7:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16211/abstract/10\">",
"      Ramirez G, Gomez-Sanchez C, Meikle WA, Jubiz W. Evaluation of the hypothalamic hypophyseal adrenal axis in patients receiving long-term hemodialysis. Arch Intern Med 1982; 142:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16211/abstract/11\">",
"      Luger A, Lang I, Kovarik J, et al. Abnormalities in the hypothalamic-pituitary-adrenocortical axis in patients with chronic renal failure. Am J Kidney Dis 1987; 9:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16211/abstract/12\">",
"      Hashimoto K, Nishioka T, Numata Y, et al. Plasma levels of corticotropin-releasing hormone in hypothalamic-pituitary-adrenal disorders and chronic renal failure. Acta Endocrinol (Copenh) 1993; 128:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16211/abstract/13\">",
"      Rosman PM, Farag A, Peckham R, et al. Pituitary-adrenocortical function in chronic renal failure: blunted suppression and early escape of plasma cortisol levels after intravenous dexamethasone. J Clin Endocrinol Metab 1982; 54:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16211/abstract/14\">",
"      Himmelfarb J, Holbrook D, McMonagle E, et al. Kt/V, nutritional parameters, serum cortisol, and insulin growth factor-1 levels and patient outcome in hemodialysis. Am J Kidney Dis 1994; 24:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16211/abstract/15\">",
"      Jusko WJ, Milad MA, Ludwig EA, et al. Methylprednisolone pharmacokinetics and pharmacodynamics in chronic renal failure. Clin Nephrol 1995; 43 Suppl 1:S16.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1976 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-9D0B6BF364-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_53_16211=[""].join("\n");
var outline_f15_53_16211=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TESTS OF ADRENAL AND PITUITARY FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACTH, CRH, and metyrapone stimulation tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dexamethasone suppression tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cortisol as a marker for treatment outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PHARMACOKINETICS OF EXOGENOUS STEROIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/43/18102?source=related_link\">",
"      Carbohydrate and insulin metabolism in chronic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_53_16212="Obturator nerve anatomy";
var content_f15_53_16212=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F64767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F64767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Obturator nerve anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 652px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_53_16212=[""].join("\n");
var outline_f15_53_16212=null;
var title_f15_53_16213="Methimazole: Patient drug information";
var content_f15_53_16213=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Methimazole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     see \"Methimazole: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/50/21286?source=see_link\">",
"     see \"Methimazole: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F194314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tapazole&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F194315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dom-Methimazole;",
"     </li>",
"     <li>",
"      PHL-Methimazole;",
"     </li>",
"     <li>",
"      Tapazole&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat an overactive thyroid gland.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702494",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to methimazole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your white blood cell, red blood cell, or platelet counts are low, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698411",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your baby's thyroid checked if you are using this drug and breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697946",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696431",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698967",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain or swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Always take with food or always take on an empty stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11222 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-5450C57513-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_53_16213=[""].join("\n");
var outline_f15_53_16213=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194314\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194315\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027810\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027809\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027814\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027815\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027817\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027812\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027813\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027818\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027819\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=related_link\">",
"      Methimazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/50/21286?source=related_link\">",
"      Methimazole: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_53_16214="Loperamide: Drug information";
var content_f15_53_16214=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Loperamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/33/41492?source=see_link\">",
"    see \"Loperamide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/31/8692?source=see_link\">",
"    see \"Loperamide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F189683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Anti-Diarrheal [OTC];",
"     </li>",
"     <li>",
"      Diamode [OTC];",
"     </li>",
"     <li>",
"      Imodium&reg; A-D EZ Chews [OTC];",
"     </li>",
"     <li>",
"      Imodium&reg; A-D for children [OTC];",
"     </li>",
"     <li>",
"      Imodium&reg; A-D [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F189684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Loperamide&reg;;",
"     </li>",
"     <li>",
"      Diarr-Eze;",
"     </li>",
"     <li>",
"      Dom-Loperamide;",
"     </li>",
"     <li>",
"      Imodium&reg;;",
"     </li>",
"     <li>",
"      Loperacap;",
"     </li>",
"     <li>",
"      Novo-Loperamide;",
"     </li>",
"     <li>",
"      PMS-Loperamine;",
"     </li>",
"     <li>",
"      Rhoxal-loperamide;",
"     </li>",
"     <li>",
"      Rho&reg;-Loperamine;",
"     </li>",
"     <li>",
"      Riva-Loperamide;",
"     </li>",
"     <li>",
"      Sandoz-Loperamide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F189727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiarrheal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F189687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute diarrhea:",
"     </b>",
"     Oral: Initial: 4 mg, followed by 2 mg after each loose stool, up to 16 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic diarrhea:",
"     </b>",
"     Oral: Initial: Follow acute diarrhea; maintenance dose should be slowly titrated downward to minimum required to control symptoms (typically, 4-8 mg/day in divided doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Traveler's diarrhea:",
"     </b>",
"     Oral: Initial: 4 mg after first loose stool, followed by 2 mg after each subsequent stool (maximum dose: 8 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cancer treatment-induced diarrhea (unlabeled use):",
"     </b>",
"     Oral: 4 mg followed by 2 mg every 4 hours or after each unformed stool; Maximum 16 mg/day (Benson, 2004)",
"     <b>",
"      or",
"     </b>",
"     4 mg followed by 2 mg every 2 hours (4 mg every 4 hours at night) until 12 hours have passed without a loose bowel movement (Sharma, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Irinotecan-induced delayed diarrhea (unlabeled use):",
"     </b>",
"     Oral: 4 mg after first loose or frequent bowel movement, then 2 mg every 2 hours (4 mg every 4 hours at night) until 12 hours have passed without a bowel movement (Rothenberg, 1996)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F189704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/31/8692?source=see_link\">",
"      see \"Loperamide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute diarrhea:",
"     </b>",
"     Initial doses (in first 24 hours):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-5 years (13-20 kg): 1 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-8 years (20-30 kg): 2 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8-12 years (&gt;30 kg): 2 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance: After initial dosing, 0.1 mg/kg doses after each loose stool, daily dose should not exceed the recommended dose for the initial 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Traveler's diarrhea:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-8 years: 2 mg after first loose stool, followed by 1 mg after each subsequent stool (maximum dose: 4 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-11 years: 2 mg after first loose stool, followed by 1 mg after each subsequent stool (maximum dose: 6 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;12 years:  Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F189688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14186587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F2127378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F189665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral, as hydrochloride: 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anti-Diarrheal: 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diamode: 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Imodium&reg; A-D: 2 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral, as hydrochloride: 1 mg/5 mL (120 mL [DSC]); 1 mg/7.5 mL (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Imodium&reg; A-D: 1 mg/7.5 mL (240 mL) [creamy-mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Imodium&reg; A-D: 1 mg/7.5 mL (120 mL) [contains sodium 10 mg/30 mL, sodium benzoate; creamy-mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Imodium&reg; A-D for children: 1 mg/7.5 mL (120 mL) [contains sodium 16 mg/30 mL, sodium benzoate; creamy-mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrochloride: 1 mg/5 mL (5 mL, 10 mL, 118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anti-Diarrheal: 1 mg/5 mL (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Imodium&reg; A-D EZ Chews: 2 mg [mint flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F189652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes chewable tablet",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F189668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Control and symptomatic relief of chronic diarrhea associated with inflammatory bowel disease and of acute nonspecific diarrhea; to reduce volume of ileostomy discharge",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OTC labeling: Control of symptoms of diarrhea, including Traveler&rsquo;s diarrhea",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F189724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cancer treatment-induced diarrhea (eg, irinotecan induced); chronic diarrhea caused by bowel resection",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F189734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Imodium&reg; A-D may be confused with Indocin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Loperamide may be confused with furosemide, Lomotil&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Indiaral [France] may be confused with Inderal and Inderal LA brand names for propranolol [U.S., Canada, and multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lomotil: Brand name for loperamide [Mexico, Philippines], but also the brand name for diphenoxylate [U.S., Canada, and multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lomotil [Mexico, Phillipines] may be confused with Ludiomil brand name for maprotiline [multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F189725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation (2% to 5%), abdominal cramping (&le;3%), nausea (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Abdominal distention, abdominal pain, allergic reactions, anaphylactic shock, anaphylactoid reactions, angioedema, bullous eruption (rare), drowsiness, dyspepsia, erythema multiforme (rare), fatigue, flatulence, hypersensitivity, paralytic ileus, megacolon, pruritus, rash, Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare), toxic megacolon, urinary retention, urticaria, vomiting, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F189671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to loperamide or any component of the formulation; abdominal pain without diarrhea; children &lt;2 years of age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avoid use as primary therapy in patients with acute dysentery (bloody stools and high fever), acute ulcerative colitis, bacterial enterocolitis (caused by",
"     <i>",
"      Salmonella, Shigella",
"     </i>",
"     , and",
"     <i>",
"      Campylobacter",
"     </i>",
"     ), pseudomembranous colitis associated with broad-spectrum antibiotic use",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F189656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergic reactions: Rare cases of anaphylaxis and anaphylactic shock have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness or dizziness, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; GI effects: Discontinue promptly if constipation, abdominal pain, abdominal distension, blood in stool, or ileus develop. Do not use when peristalsis inhibition should be avoided due to potential for ileus, megacolon and/or toxic megacolon.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; AIDS patients: Stop therapy at the first sign of abdominal distention; cases of toxic megacolon have occurred in AIDS patients with infectious colitis (due to viral or bacterial pathogens).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment due to reduced first-pass metabolism; monitor for signs of CNS toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with caution in young children as response may be variable because of dehydration. Contraindicated in children &lt;2 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Loperamide is a symptom-directed treatment; if an underlying diagnosis is made, other disease-specific treatment may be indicated. Contraindicated if diarrhea is accompanied by high fever or blood in stool. Should not be used when inhibition of peristalsis is undesirable or dangerous. Concurrent fluid and electrolyte replacement is often necessary in all age groups depending upon severity of diarrhea. If improvement in acute diarrhea does not occur in 2 days, discontinue use and consult healthcare provider.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Duration of use: If diarrhea lasts longer than 2 days, symptoms worsen, or abdominal swelling or bulging develops, discontinue use and consult healthcare provider.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F2127373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F189661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F189662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2127372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. Information related to loperamide use in pregnancy is limited and data is conflicting (Einarson, 2000; K&auml;ll&eacute;n, 2008). For acute diarrhea in pregnant women, some clinicians recommend oral rehydration and dietary changes; loperamide in small amounts may be used only if symptoms are disabling (Wald, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F189691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP considers &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14186532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of loperamide are excreted in human breast milk (information is based on studies using loperamide oxide, the prodrug of loperamide [Nikodem, 1992]). The manufacturer does not recommend use in nursing women. The AAP considers loperamide to be &ldquo;usually compatible with breast-feeding&rdquo; (AAP, 2001; update pending).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F1623722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F189673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Loperamide HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $70.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Imodium A-D Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (20): $7.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Imodium A-D Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/7.5 mL (120 mL): $4.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Loperamide HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/5 mL (118 mL): $5.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Imodium A-D Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (24): $7.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Loperamide A-D Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (12): $1.88",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F189674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Amerol (ID);",
"     </li>",
"     <li>",
"      Arestal (KP);",
"     </li>",
"     <li>",
"      Beamodium (MY);",
"     </li>",
"     <li>",
"      Betaperamide (ZA);",
"     </li>",
"     <li>",
"      Binaldan (CH);",
"     </li>",
"     <li>",
"      Colidium (ID);",
"     </li>",
"     <li>",
"      Colifilm (AR);",
"     </li>",
"     <li>",
"      Coliper (CN);",
"     </li>",
"     <li>",
"      D-Stop-ratiopharm (LU);",
"     </li>",
"     <li>",
"      Diadium (ID);",
"     </li>",
"     <li>",
"      Diamide (NZ);",
"     </li>",
"     <li>",
"      Diaperol (MX);",
"     </li>",
"     <li>",
"      Diarlop (IN);",
"     </li>",
"     <li>",
"      Diarodil (TH);",
"     </li>",
"     <li>",
"      Diatabs (PH);",
"     </li>",
"     <li>",
"      Diatrol (SG);",
"     </li>",
"     <li>",
"      Dissenten (IT);",
"     </li>",
"     <li>",
"      Donafan (PE);",
"     </li>",
"     <li>",
"      Dyspagon (LU);",
"     </li>",
"     <li>",
"      Elcoman (AR);",
"     </li>",
"     <li>",
"      Fortasec (ES);",
"     </li>",
"     <li>",
"      Gastro-Stop (AU);",
"     </li>",
"     <li>",
"      Gastron (ZA);",
"     </li>",
"     <li>",
"      Harmonise (AU);",
"     </li>",
"     <li>",
"      Imodium (AE, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BS, CH, CI, CL, CO, CY, CZ, DE, DK, EE, EG, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HU, ID, IE, IL, IN, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NL, NO, NZ, OM, PE, PH, PK, PL, PR, PT, PY, QA, RU, SA, SC, SD, SE, SG, SL, SN, SR, SY, TH, TN, TT, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Imodonil (HK);",
"     </li>",
"     <li>",
"      Imonox (TH);",
"     </li>",
"     <li>",
"      Imosec (BR);",
"     </li>",
"     <li>",
"      Imosen (TW);",
"     </li>",
"     <li>",
"      Imossel (FR);",
"     </li>",
"     <li>",
"      Lenide-T (ZA);",
"     </li>",
"     <li>",
"      Lodia (ID);",
"     </li>",
"     <li>",
"      Lomotil (MX);",
"     </li>",
"     <li>",
"      Lopamide (IN);",
"     </li>",
"     <li>",
"      Lopedin (TW);",
"     </li>",
"     <li>",
"      Lopedium (HU, LU);",
"     </li>",
"     <li>",
"      Lopemid (IT);",
"     </li>",
"     <li>",
"      Loper (HK);",
"     </li>",
"     <li>",
"      Loperamid-ratiopharm (LU);",
"     </li>",
"     <li>",
"      Loperamide-Eurogenerics (LU);",
"     </li>",
"     <li>",
"      Loperamide-Generics (LU);",
"     </li>",
"     <li>",
"      Loperamil (HK, SG);",
"     </li>",
"     <li>",
"      Loperhoe (DE);",
"     </li>",
"     <li>",
"      Loperium (BB, BM, BS, BZ, GY, JM, NL, SR, TT);",
"     </li>",
"     <li>",
"      Lopermid (TR);",
"     </li>",
"     <li>",
"      Lopermide (HK);",
"     </li>",
"     <li>",
"      Lopicare (IL);",
"     </li>",
"     <li>",
"      Lopmin (KP);",
"     </li>",
"     <li>",
"      Loprex (IL);",
"     </li>",
"     <li>",
"      Loramide (SG);",
"     </li>",
"     <li>",
"      Luobaomai (CL);",
"     </li>",
"     <li>",
"      Motilex (ID);",
"     </li>",
"     <li>",
"      NT-Diorea (HK);",
"     </li>",
"     <li>",
"      Pangetan NF (CO);",
"     </li>",
"     <li>",
"      Perasian (TH);",
"     </li>",
"     <li>",
"      Permid (PH);",
"     </li>",
"     <li>",
"      Regulane (AR);",
"     </li>",
"     <li>",
"      Rexamide (IL);",
"     </li>",
"     <li>",
"      Reximide (MY);",
"     </li>",
"     <li>",
"      Rhomuz (ID);",
"     </li>",
"     <li>",
"      Safe (TW);",
"     </li>",
"     <li>",
"      Salvacolina (DO, ES, GT, HN, PA, SV);",
"     </li>",
"     <li>",
"      Sanpo (TW);",
"     </li>",
"     <li>",
"      Seldiar (HR);",
"     </li>",
"     <li>",
"      Shilshul X2 (IL);",
"     </li>",
"     <li>",
"      Stopit (IL);",
"     </li>",
"     <li>",
"      Suprasec (AR);",
"     </li>",
"     <li>",
"      Toban (PE);",
"     </li>",
"     <li>",
"      Toban F (PE);",
"     </li>",
"     <li>",
"      Undiarrhea (TW);",
"     </li>",
"     <li>",
"      Vacontil (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, JO, KE, KW, LB, LR, MA, ML, MR, MU, MW, MY, NE, NG, OM, QA, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Vancotil (SG);",
"     </li>",
"     <li>",
"      Velaral (EC)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F189655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acts directly on circular and longitudinal intestinal muscles, through the opioid receptor, to inhibit peristalsis and prolong transit time; reduces fecal volume, increases viscosity, and diminishes fluid and electrolyte loss; demonstrates antisecretory activity. Loperamide increases tone on the anal sphincter",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F189670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Poor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Poor penetration into brain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via oxidative N-demethylation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 9-14 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Liquid: 2.5 hours; Capsule: 5 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abigerges D, Armand JP, Chabot GG, et al, &ldquo;Irinotecan (CPT-11) High-Dose Escalation Using Intensive High-Dose Loperamide to Control Diarrhea,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 1994, 86(6):446-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/53/16214/abstract-text/8120919/pubmed\" id=\"8120919\" target=\"_blank\">",
"        8120919",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/53/16214/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Benson AB 3rd, Ajani JA, Catalano RB, et al, \"Recommended Guidelines for the Treatment of Cancer Treatment-Induced Diarrhea,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(14):2918-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/53/16214/abstract-text/15254061/pubmed\" id=\"15254061\" target=\"_blank\">",
"        15254061",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Einarson A, Mastroiacovo P, Arnon J, et al, \"Prospective, Controlled, Multicentre Study of Loperamide in Pregnancy,\"",
"      <i>",
"       Can J Gastroenterol",
"      </i>",
"      , 2000, 14(3):185-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/53/16214/abstract-text/10758415/pubmed\" id=\"10758415\" target=\"_blank\">",
"        10758415",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ericsson CD, \"Nonantimicrobial Agents in the Prevention and Treatment of Traveler's Diarrhea,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(Suppl 8):557-63.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ericsson CD and Johnson PC, &ldquo;Safety and Efficacy of Loperamide,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1990, 88(6A):10S-14S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/53/16214/abstract-text/2192552/pubmed\" id=\"2192552\" target=\"_blank\">",
"        2192552",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      K&auml;ll&eacute;n B, Nilsson E, and Otterblad Olausson P, \"Maternal Use of Loperamide in Early Pregnancy and Delivery Outcome,\"",
"      <i>",
"       Acta Paediatr",
"      </i>",
"      ,  2008, 97(5):541-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/53/16214/abstract-text/18394096/pubmed\" id=\"18394096\" target=\"_blank\">",
"        18394096",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kornblau S, Benson AB, Catalano R, et al, &ldquo;Management of Cancer Treatment-Related Diarrhea. Issues and Therapeutic Strategies,&rdquo;",
"      <i>",
"       J Pain Symptom Manage",
"      </i>",
"      , 2000, 19(2):118-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/53/16214/abstract-text/10699539/pubmed\" id=\"10699539\" target=\"_blank\">",
"        10699539",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nikodem VC and Hofmeyr GJ, \"Secretion of the Antidiarrhoeal Agent Loperamide Oxide in Breast Milk,\"",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1992, 42(6):695-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/53/16214/abstract-text/1623917/pubmed\" id=\"1623917\" target=\"_blank\">",
"        1623917",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rothenberg ML, Eckardt JR, Kuhn JG, et al, \"Phase II Trial of Irinotecan in Patients With Progressive or Rapidly Recurrent Colorectal Cancer,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14(4):1128-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/53/16214/abstract-text/8648367/pubmed\" id=\"8648367\" target=\"_blank\">",
"        8648367",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sharma R, Tobin P, and Clarke SJ, &ldquo;Management of Chemotherapy-Induced Nausea, Vomiting, Oral Mucositis, and Diarrhoea,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2005, 6(2):93-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/53/16214/abstract-text/15683818/pubmed\" id=\"15683818\" target=\"_blank\">",
"        15683818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wald A, \"Constipation, Diarrhea, and Symptomatic Hemorrhoids During Pregnancy,\"",
"      <i>",
"       Gastroenterol Clin North Am",
"      </i>",
"      , 2003, 32(1):309-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/53/16214/abstract-text/12635420/pubmed\" id=\"12635420\" target=\"_blank\">",
"        12635420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9571 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-AF7A4312D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_53_16214=[""].join("\n");
var outline_f15_53_16214=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189683\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189684\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189727\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189687\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189704\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189688\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14186587\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127378\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189665\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189652\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189668\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189724\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189734\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189725\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189671\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189656\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127373\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189661\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189662\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127372\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189691\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14186532\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1623722\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189673\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189674\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189655\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189670\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9571\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9571|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/33/41492?source=related_link\">",
"      Loperamide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/31/8692?source=related_link\">",
"      Loperamide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_53_16215="Diagnosis and treatment of vasculitic neuropathy";
var content_f15_53_16215=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and treatment of vasculitic neuropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/53/16215/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/53/16215/contributors\">",
"     Steven David Brass, MD, MPH, FRCP(C)",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/53/16215/contributors\">",
"     Simon M Helfgott, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/53/16215/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/53/16215/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/53/16215/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/53/16215/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/53/16215/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/53/16215/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasculitic diseases can affect any organ or tissue, including the peripheral nerves. When vasculitis affects the vasa nervorum, the results are often critical ischemia to peripheral nerves and potentially profound clinical sequelae.",
"   </p>",
"   <p>",
"    Vasculitic neuropathy is usually only one feature of a systemic condition that can involve the skin, lungs, kidneys, and other organs. As an example, the group of vasculitic disorders commonly associated with antineutrophil cytoplasmic antibodies (ANCA) (ie, granulomatosis with polyangiitis [Wegener&rsquo;s], microscopic polyangiitis, and the Churg-Strauss syndrome) often cause vasculitic neuropathy. Polyarteritis nodosa (PAN) and mixed cryoglobulinemia are also prone to involve the peripheral nervous system.",
"   </p>",
"   <p>",
"    In a minority of patients with vasculitic neuropathy, the peripheral nervous system vasculitis occurs in isolation. In this setting, the disorder is referred to as nonsystemic vasculitic neuropathy or isolated peripheral nervous system vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16215/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even in the absence of frank systemic vasculitis, nonsystemic vasculitic neuropathy can be a devastating illness, leading to severe functional disabilities from which some patients never recover fully. Because the regeneration of peripheral nerves may require months or years, the goals of therapy are to control the inflammation within the vasa nervorum as quickly as possible to prevent or minimize nerve damage.",
"   </p>",
"   <p>",
"    This topic will review the diagnosis and treatment of vasculitic peripheral neuropathy. The clinical manifestations of vasculitic neuropathy are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=see_link\">",
"     \"Clinical manifestations of vasculitic neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic evaluation of the patient with suspected vasculitic neuropathy includes a thorough medical history, physical examination, selected laboratory tests, and neurophysiologic testing with nerve conduction studies and electromyography. The gold standard for the diagnosis of vasculitic neuropathy is nerve biopsy, often performed in conjunction with muscle biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough review of systems should include questions related to the other organs commonly involved by systemic vasculitis, particularly the eyes (redness, pain, visual loss); ears (hearing dysfunction, otalgia); nose (congestion, crusts, epistaxis); mouth (oral ulcers, gum inflammation); lungs (cough, hemoptysis); and skin (rash, livedo reticularis, ulcers). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link\">",
"     \"Classification of and approach to the vasculitides in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40616?source=see_link\">",
"     \"Classification and incidence of childhood vasculitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough physical examination may detect findings compatible with a systemic vasculitis. Patients with vasculitic neuropathies may be unaware of focal nerve dysfunction, particularly if other organ manifestations such as arthritis, sinusitis, or skin ulcers dominate the clinical picture. Objective evidence of motor weakness, such as foot-drop, wrist-drop, or loss of deep tendon reflexes, should be sought. In the absence of diabetes, a mononeuritis multiplex is highly suggestive of vasculitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations of vasculitic neuropathy\", section on 'Mononeuritis multiplex'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing may be useful diagnostically in cases of suspected vasculitic neuropathy. Diagnostic laboratory tests should be selected that support or help exclude systemic conditions that may be suggested by the history and physical examination.",
"   </p>",
"   <p>",
"    The following tests may be valuable:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count and differential",
"     </li>",
"     <li>",
"      Serum creatinine and estimation of glomerular filtration rate",
"     </li>",
"     <li>",
"      Urinalysis, with microscopic examination of urinary sediment",
"     </li>",
"     <li>",
"      Antinuclear antibody (ANA) assay",
"     </li>",
"     <li>",
"      ANCA",
"     </li>",
"     <li>",
"      Antibodies to double stranded DNA (dsDNA)",
"     </li>",
"     <li>",
"      Antibodies to extractable nuclear antigens (anti-Sm,",
"      <span class=\"nowrap\">",
"       anti-Ro/SSA,",
"      </span>",
"      <span class=\"nowrap\">",
"       anti-La/SSB,",
"      </span>",
"      and anti-RNP)",
"     </li>",
"     <li>",
"      Rheumatoid factor",
"     </li>",
"     <li>",
"      Cryoglobulins",
"     </li>",
"     <li>",
"      Tests for hepatitis B and hepatitis C virus infections",
"     </li>",
"     <li>",
"      Lyme disease assays",
"     </li>",
"     <li>",
"      Complement components (C3 and C4)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     ANA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of antinuclear antibodies is nonspecific but compatible with the presence of a connective tissue disease, such as systemic lupus erythematosus, rheumatoid arthritis, or Sj&ouml;gren's syndrome. Patients with cryoglobulinemia and ANCA-associated vasculitides may also be ANA positive. If the ANA titer is high (eg, &gt;1:160), further investigation is indicated to define more precisely the specific antibody responsible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28520?source=see_link\">",
"     \"Measurement and clinical significance of antinuclear antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Specific ANAs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of autoantibodies to dsDNA, Sm antigen, or ribonucleoprotein (RNP) is compatible with, but is not diagnostic of, SLE. The presence of antibodies to",
"    <span class=\"nowrap\">",
"     Ro/SSA",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     La/SSB",
"    </span>",
"    antigens can be seen in patients with Sj&ouml;gren's syndrome or in those with SLE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1192?source=see_link\">",
"     \"Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8568?source=see_link\">",
"     \"The anti-Ro/SSA and anti-La/SSB antigen-antibody systems\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     ANCA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive ANCA test is seen in the majority of patients with granulomatosis with polyangiitis (Wegener&rsquo;s) or microscopic polyangiitis, as well as in a substantial proportion of those with Churg-Strauss syndrome. In contrast, patients with classic polyarteritis nodosa are ANCA-negative. However, ANCA positivity alone is not sufficient to make a diagnosis, particularly if directed against myeloperoxidase (MPO). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cryoglobulins and RF",
"    </span>",
"    &nbsp;&mdash;&nbsp;In mixed cryoglobulinemia, in which the precipitate is generally comprised of monoclonal IgM and polyclonal IgG components, the IgM invariably demonstrates rheumatoid factor (RF) activity (ie, reactivity to the Fc portion of IgG). As a result, all patients with mixed cryoglobulinemia are RF positive, often strikingly so. RF positivity is also consistent with rheumatoid arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Electrodiagnostic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrodiagnostic testing in vasculitic neuropathy is characterized by axonal damage involving multiple individual nerves in an asymmetric fashion. More proximal involvement at the level of nerve roots or of the cervical or lumbar nerve plexus can also occur.",
"   </p>",
"   <p>",
"    The following electrodiagnostic features are typically noted in vasculitic neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16215/abstract/3,5-7\">",
"     3,5-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nerve conduction studies in patients with vasculitic neuropathy reveal low amplitude sensory nerve action potentials, low amplitude compound muscle action potentials, and either normal or slightly slow nerve conduction velocities.",
"     </li>",
"     <li>",
"      Electromyographic examination of affected muscle may show diffuse signs of denervation with fibrillations and positive sharp waves.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nerve/muscle biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the clinical presentation is compatible with that of a vasculitic neuropathy and if there is histopathologic or angiographic evidence of vasculitis in other organs combined,",
"    <span class=\"nowrap\">",
"     nerve/muscle",
"    </span>",
"    biopsy may not be necessary to confirm the clinical diagnosis. Biopsy may be necessary in patients lacking these features.",
"   </p>",
"   <p>",
"    Vasculitic neuropathy can be demonstrated on nerve",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    muscle biopsy. Because the simultaneous performance of these two biopsies increases the overall yield of the procedure, adjacent nerves and muscles are usually biopsied together. Common",
"    <span class=\"nowrap\">",
"     nerve/muscle",
"    </span>",
"    biopsy combinations are the sural nerve and gastrocnemius muscle, and the peroneal nerve and peroneus brevis muscle.",
"   </p>",
"   <p>",
"    In a study of 48 patients with nonsystemic (ie, isolated) vasculitic neuropathy, combined peroneal nerve and peroneus brevis muscle biopsy had a modestly higher sensitivity than nerve biopsy alone (58 versus 47 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16215/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations of vasculitic neuropathy\", section on 'Nonsystemic vasculitic neuropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Persistent anesthesia of the skin supplied by the nerve that is biopsied is an expected side effect of nerve biopsy. In a minority of cases, nerve biopsy is followed by chronic pain [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16215/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mononeuritis multiplex has a limited differential diagnosis, which includes diabetes mellitus, inflammatory demyelinating polyneuropathy, multiple nerve entrapments, infection (eg, Lyme disease, leprosy), and nerve infiltration (eg, sarcoid, lymphoma, leukemia).",
"   </p>",
"   <p>",
"    In contrast, the differential diagnosis of symmetrical, small-fiber polyneuropathies is extensive and includes both common entities (eg, diabetic or alcoholic polyneuropathy) and rare disorders (eg, toxins). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8712?source=see_link\">",
"     \"Differential diagnosis of peripheral nerve and muscle disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT OF NONSYSTEMIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;When vasculitic neuropathy is associated with an identifiable systemic vasculitis or connective tissue disease, immunosuppressive therapy is directed at the underlying disease as described elsewhere in the appropriate topic reviews. In such patients, only issues such as rehabilitation and analgesia are specific for the neuropathy. The following discussion will focus on the treatment of nonsystemic (ie, isolated) vasculitic neuropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations of vasculitic neuropathy\", section on 'Nonsystemic vasculitic neuropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 2007 review from the Cochrane database concluded that there are no adequate randomized or quasi-randomized controlled clinical trials on which to base treatment for nonsystemic vasculitic neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16215/abstract/10\">",
"     10",
"    </a>",
"    ]. Thus, therapeutic decisions are based primarily on clinical experience, observational data, and extrapolation from trials of immunosuppressive agents in systemic vasculitis and connective tissue diseases.",
"   </p>",
"   <p>",
"    For patients with mild vasculitic neuropathy, high-dose glucocorticoids may suffice to control the disease. However, because vasculitic neuropathy signals the presence of a severe inflammatory syndrome that has major potential for both short- and long-term morbidity and death, we suggest the combined use of glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    in most patients, particularly those in whom there is motor nerve dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;High doses of glucocorticoids are required. The choice of agent, dose, frequency, route of administration, and duration are generally selected on an empiric basis, determined in part by both the type of vasculitis and the severity of nerve dysfunction.",
"   </p>",
"   <p>",
"    A widely used regimen begins with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, up to a maximum daily dose of 80 mg). This regimen is continued for four weeks with ongoing assessment of the clinical response. The initial prednisone dose should not be continued beyond four weeks because of the potential for glucocorticoid-related morbidity, including muscle weakness, which may interfere with interpretation of the clinical response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Tapering regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no standard tapering regimen for vasculitic neuropathy, but regimens similar to the one outlined below are often used. Assuming that a patient begins",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at 60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and remains on this dose for four weeks, the following taper will require a total of 24 weeks to reach a daily dose of 5 mg:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose is tapered by 10 mg each week until a dose of 40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      is reached.",
"     </li>",
"     <li>",
"      After one week on 40",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose is tapered by 5 mg each week until the dose reaches 20",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      After one week on 20",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose is tapered by 2.5 mg each week until the dose reaches 10",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      After one week on 10",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose is tapered by 1 mg every two weeks until the dose reaches 5",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patient should be monitored carefully during the tapering period by watching for signs of recurrent nerve dysfunction or the development of inflammatory disease in other organ systems.",
"   </p>",
"   <p>",
"    Another important point is that new nerve infarctions can occur in distributions of extensive vascular compromise up to several weeks after the institution of effective therapy (eg, high-dose glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ). Thus, the development of a new nerve infarction shortly after starting immunosuppression does not necessarily signal the need to intensify treatment, particularly if other indicators of disease activity suggest disease control.",
"   </p>",
"   <p>",
"    Continuation of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    taper can be considered if the patient has achieved and maintained good disease control. Tapering off prednisone completely should not proceed faster than 1",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    decreases every two weeks. Deviations from this regimen are often necessary if patients develop glucocorticoid myopathy or experience disease flares. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=see_link\">",
"     \"Glucocorticoid-induced myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pulse glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with severe systemic vasculitis or connective tissue disease that poses an immediate threat to the patient's life, pulse glucocorticoid therapy may be indicated. No controlled clinical trials of this approach have been performed, but, in extrapolation from other clinical experience in the treatment of other inflammatory disorders, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    intravenously for three days. Following the completion of the glucocorticoid pulse, treatment with daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    may begin as outlined above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with nonsystemic vasculitic neuropathy are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    as well as glucocorticoids, particularly those with motor nerve dysfunction. The general approach is to establish disease control as quickly as possible through combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and then to discontinue cyclophosphamide after three to six months. Cyclophosphamide is replaced by a medication with a lower risk of toxicity, usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    We suggest initiating oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy at a dose of 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, with dose adjustments for patients with decreased renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16215/abstract/1\">",
"     1",
"    </a>",
"    ]. The principal advantage of oral dosing of cyclophosphamide is that the daily dose can be titrated according to the white blood cell count so as to avoid neutropenia. However, the induction of remission appears equally likely regardless of whether oral (daily) or intravenous (intermittent) cyclophosphamide is used. The choice of oral versus intravenous cyclophosphamide is dictated primarily by practice style. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients treated with the combination of high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    should receive prophylaxis against Pneumocystis carinii infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the toxicity of long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy, a number of less toxic drugs have been used for maintenance therapy after disease control has been attained with cyclophosphamide. The use of some of these drugs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ) is based upon their proven value as maintenance therapy in granulomatosis with polyangiitis (Wegener&rsquo;s). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      &mdash; Before beginning azathioprine, patients should be screened for thiopurine methyltransferase (TPMT) deficiencies. Patients deficient in one or both alleles of the TPMT enzyme have impaired ability to metabolize azathioprine, leading to potentially severe or life-threatening adverse effects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link&amp;anchor=H2#H2\">",
"       \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Pharmacology'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      We suggest a gradual increase in the azathioprine dose. The initial dose of azathioprine is 50",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      If this dose is tolerated well at one week, the daily dose can be increased over several weeks to the range of 1.5 to 3.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day. Most clinicians do not prescribe more than 200",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      even for large individuals.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      &mdash; The initial methotrexate dose is usually 15",
"      <span class=\"nowrap\">",
"       mg/week,",
"      </span>",
"      with increases in dose every week of 5",
"      <span class=\"nowrap\">",
"       mg/week",
"      </span>",
"      up to 25",
"      <span class=\"nowrap\">",
"       mg/week.",
"      </span>",
"      This regimen is similar to that used in rheumatoid arthritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link\">",
"       \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We attempt to discontinue all immunosuppressive medications eventually after disease remission has been achieved and a disease-free period of suitable length (eg, 6 to 12 months) has elapsed.",
"   </p>",
"   <p>",
"    Most patients and clinicians prefer to discontinue glucocorticoids before stopping the other maintenance immunosuppressive medicine. Attempts to discontinue",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    are reasonable in patients who have achieved remission that is sustained after the cessation of glucocorticoids. There is no physiologic reason why azathioprine or methotrexate needs to be tapered. Stopping these medications abruptly at a time deemed appropriate is an accepted practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rehabilitation efforts, including physical and occupational therapy consultation, should begin as early as possible. An ankle foot orthosis or wrist splint may be helpful in allowing patients to re-establish useful function in an affected extremity while awaiting neurologic recovery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link\">",
"     \"Splinting of musculoskeletal injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pain associated with the vasculitic neuropathy may be severe. A number of pain modifying agents may be considered, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    . In more severe cases, opioid analgesics are required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term outcomes in patients with vasculitic neuropathy were evaluated in a retrospective review of 106 patients (only 11 nonsystemic) collected over 28 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16215/abstract/4\">",
"     4",
"    </a>",
"    ]. Glucocorticoids formed the cornerstone of treatment in this patient cohort, while approximately one-half of the patients also received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    via either the intravenous or oral route.",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Remission was achieved in all but six patients.",
"     </li>",
"     <li>",
"      One-year survival was 90 percent.",
"     </li>",
"     <li>",
"      The neurologic relapse rate was 10 percent, but only one relapse occurred in a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      -treated patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the efficacy of remission induction in this study, 23 percent of the patients were judged to have poor outcomes, defined as either death related to the disease or treatment or as the development of disability classified as moderate or worse. Poor outcomes in vasculitic neuropathy relate both to delay in diagnosis and to the adverse effects of treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    Vasculitic neuropathy results from inflammation that develops within the blood vessel walls of the vasa nervorum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful history, physical examination, and selected laboratory assays designed to diagnose or exclude systemic vasculitides and connective tissue diseases are important parts of the evaluation. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Diagnostic evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Electromyography and nerve conduction studies help distinguish nerve dysfunction from muscular causes of weakness and are useful in identifying characteristic patterns of peripheral nerve disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations of vasculitic neuropathy\", section on 'Patterns of nerve involvement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The gold standard for the diagnosis of vasculitic neuropathy is a nerve biopsy, usually performed in conjunction with a muscle biopsy. Patients with biopsy-proven vasculitis in other organs and presentations of nerve dysfunction typical of vasculitis do not require nerve biopsies. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Nerve/muscle biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;When vasculitic neuropathy is associated with an identifiable systemic vasculitis or connective tissue disease, immunosuppressive therapy is directed at the underlying disease as described elsewhere in the appropriate topic reviews. In such patients, only issues such as rehabilitation and analgesia are specific for the neuropathy.",
"   </p>",
"   <p>",
"    The following discussion will focus on the treatment of nonsystemic (ie, isolated) vasculitic neuropathy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that patients with nonsystemic vasculitic neuropathy be treated with an immunosuppressive regimen that includes high-dose glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For patients with mild nonsystemic vasculitic neuropathy, high-dose glucocorticoids may suffice to control the disease. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with moderate to severe nonsystemic vasculitic neuropathy, particularly those with motor nerve involvement, we suggest using the combination of high-dose glucocorticoids and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Glucocorticoids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Cyclophosphamide'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The initial dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      is typically 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, up to a maximum daily dose of 80 mg. For patients with severe vasculitic neuropathy, we suggest using pulse",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      1000",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      intravenously for three days at the start of treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Pulse glucocorticoid therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      is 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, with dose adjustments for patients with decreased renal function. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Cyclophosphamide'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link\">",
"       \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    is typically tapered over six months. The taper may be extended if non-neurologic features of the patient's underlying disease dictate a longer course of glucocorticoid treatment. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Tapering regimen'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    After three to six months of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , we recommend discontinuing this medication in favor of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Maintenance therapy'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16215/abstract/1\">",
"      Dyck PJ, Benstead TJ, Conn DL, et al. Nonsystemic vasculitic neuropathy. Brain 1987; 110 ( Pt 4):843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16215/abstract/2\">",
"      Collins MP, Periquet MI. Non-systemic vasculitic neuropathy. Curr Opin Neurol 2004; 17:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16215/abstract/3\">",
"      Davies L, Spies JM, Pollard JD, McLeod JG. Vasculitis confined to peripheral nerves. Brain 1996; 119 ( Pt 5):1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16215/abstract/4\">",
"      Mathew L, Talbot K, Love S, et al. Treatment of vasculitic peripheral neuropathy: a retrospective analysis of outcome. QJM 2007; 100:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16215/abstract/5\">",
"      Lie JT. Histopathologic specificity of systemic vasculitis. Rheum Dis Clin North Am 1995; 21:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16215/abstract/6\">",
"      Moore PM. Vasculitis: diagnosis and therapy. Semin Neurol 1994; 14:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16215/abstract/7\">",
"      Olney RK. AAEM minimonograph #38: neuropathies in connective tissue disease. Muscle Nerve 1992; 15:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16215/abstract/8\">",
"      Collins MP, Periquet MI, Mendell JR, et al. Nonsystemic vasculitic neuropathy: insights from a clinical cohort. Neurology 2003; 61:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16215/abstract/9\">",
"      Collins MP, Mendell JR, Periquet MI, et al. Superficial peroneal nerve/peroneus brevis muscle biopsy in vasculitic neuropathy. Neurology 2000; 55:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16215/abstract/10\">",
"      Vrancken AF, Hughes RA, Said G, et al. Immunosuppressive treatment for non-systemic vasculitic neuropathy. Cochrane Database Syst Rev 2007; :CD006050.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8221 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.218.100.194-EFEE8658EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_53_16215=[""].join("\n");
var outline_f15_53_16215=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - ANA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Specific ANAs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - ANCA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cryoglobulins and RF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Electrodiagnostic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nerve/muscle biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT OF NONSYSTEMIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Tapering regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pulse glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1192?source=related_link\">",
"      Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40616?source=related_link\">",
"      Classification and incidence of childhood vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=related_link\">",
"      Clinical manifestations of vasculitic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8712?source=related_link\">",
"      Differential diagnosis of peripheral nerve and muscle disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=related_link\">",
"      Glucocorticoid-induced myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/23/6521?source=related_link\">",
"      Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28520?source=related_link\">",
"      Measurement and clinical significance of antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=related_link\">",
"      Splinting of musculoskeletal injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8568?source=related_link\">",
"      The anti-Ro/SSA and anti-La/SSB antigen-antibody systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_53_16216="Digit dislocation reduction";
var content_f15_53_16216=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Digit dislocation reduction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/53/16216/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/53/16216/contributors\">",
"     Samir V Joshi, MD, DCH, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/53/16216/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/53/16216/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/53/16216/contributors\">",
"     Allan B Wolfson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/53/16216/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/53/16216/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/53/16216/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dislocation of a digit is common among skeletally mature adolescents and active young adults. Dorsal displacement of the proximal interphalangeal joint of the finger is the most frequent dislocation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/1\">",
"     1",
"    </a>",
"    ]. On the other hand, double dislocations of the finger interphalangeal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metacarpophalangeal joints are a rare entity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/2\">",
"     2",
"    </a>",
"    ]. The primary management of digital joint dislocations consists of radiographic exclusion of a fracture, joint reduction after appropriate analgesia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    regional anesthesia, and splinting.",
"   </p>",
"   <p>",
"    The reduction of digit dislocations is reviewed here. The treatment of toe and finger fractures is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/35/14903?source=see_link\">",
"     \"Metatarsal and toe fractures in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44358?source=see_link\">",
"     \"Toe fractures in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20037?source=see_link\">",
"     \"Proximal phalanx fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40885?source=see_link\">",
"     \"Middle phalanx fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42197?source=see_link\">",
"     \"Distal phalanx fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Finger function involves a complex interaction among multiple joints, flexor and extensor tendons, and supporting fascia and ligaments. Each of the digits, except the thumb, has three phalanges with three hinged joints: distal interphalangeal (DIP), proximal interphalangeal (PIP), and metacarpophalangeal (MCP) (",
"    <a class=\"graphic graphic_figure graphicRef51990 \" href=\"UTD.htm?4/46/4838\">",
"     figure 1",
"    </a>",
"    ). Joint stability is provided by the structure of the phalanges, joint capsule, radial and ulnar collateral ligaments, and dorsal and palmar ligaments. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42645?source=see_link\">",
"     \"Finger and thumb anatomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Flexion and extension are the primary movements of the fingers. Abduction and adduction can be performed at the MCP joints. The thumb is capable of opposition, abduction, adduction, and retropulsion, in addition to flexion and extension.",
"   </p>",
"   <p>",
"    At the metacarpophalangeal (MCP) joints, lateral motion is limited by the collateral ligaments, which are actually lateral oblique in position rather than true lateral. Triangular in shape, these ligaments arise from the lateral head of each metacarpal bone and attach to the base of the proximal phalanx distally. Because of these anatomical features, the MCP joint is more stable in flexion than in extension due to stabilization by the collateral ligaments (",
"    <a class=\"graphic graphic_figure graphicRef80299 \" href=\"UTD.htm?4/10/4261\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/3\">",
"     3",
"    </a>",
"    ]. The volar plate is part of the joint capsule that attaches only to the proximal phalanx, allowing hyperextension. The volar plate is the site of insertion for the intermetacarpal ligaments. The intermetacarpal ligaments restrict the separation of the metacarpal heads.",
"   </p>",
"   <p>",
"    At the PIP and DIP joints, extension is limited by the volar plate, which attaches to the phalanges at each side of the joint and by the extensor hood (ligamentous) complex (",
"    <a class=\"graphic graphic_figure graphicRef77114 \" href=\"UTD.htm?18/14/18659\">",
"     figure 3",
"    </a>",
"    ). Radial and ulnar motion is restricted by collateral ligaments, which remain tight throughout the finger's range of motion.",
"   </p>",
"   <p>",
"    By convention, toes and their respective metatarsals are numbered from one (great toe) through five (little toe). The second through fifth toes typically have three phalanges, while the great toe has two. Lesser toes, especially the fifth, may occasionally have only two phalanges (",
"    <a class=\"graphic graphic_figure graphicRef71857 \" href=\"UTD.htm?2/20/2375\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The ligamentous complexes of the metatarsal, PIP, and DIP joints are similar to the fingers; each joint is stabilized by collateral, extensor, and plantar ligaments [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/4\">",
"     4",
"    </a>",
"    ]. In contrast to the MCP joint, the ligamentous anatomy of the metatarsal joint allows less abduction or adduction and opposition cannot occur [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/4\">",
"     4",
"    </a>",
"    ]. Dislocations of the hallucal interphalangeal joint of the great toe are rare and frequently complicated by sesamoid and plantar ligament entrapment [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In skeletally immature children, the digit's growth plates are weaker than the supporting ligaments (",
"    <a class=\"graphic graphic_figure graphicRef79444 \" href=\"UTD.htm?26/18/26918\">",
"     figure 5",
"    </a>",
"    ). Thus, Salter-Harris digit fractures are more common than dislocations (",
"    <a class=\"graphic graphic_figure graphicRef54582 \" href=\"UTD.htm?20/55/21361\">",
"     figure 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61198 \" href=\"UTD.htm?2/28/2496\">",
"     image 1",
"    </a>",
"    ). When digit dislocations do occur, they are commonly accompanied by avulsion fractures because the collateral ligaments of the MCP, PIP, and DIP joints insert into the epiphyseal regions of the growth plate (",
"    <a class=\"graphic graphic_figure graphicRef79444 \" href=\"UTD.htm?26/18/26918\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef63865 \" href=\"UTD.htm?21/51/22321\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dislocations of the digits are classified by the direction of dislocation as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dorsal",
"      </strong>",
"      &ndash; Distal digit displacement is toward the back of the hand or the top of the foot.",
"     </li>",
"     <li>",
"      <strong>",
"       Volar",
"      </strong>",
"      &ndash; Distal digit displacement is toward the palm of the hand or the sole of the foot.",
"     </li>",
"     <li>",
"      <strong>",
"       Lateral",
"      </strong>",
"      &ndash; Distal digit displacement is in the ulnar or radial direction relative to the proximal digit in the hand or in the tibial or fibular direction in the foot.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Metacarpophalangeal (MCP) dislocations, other than thumb dislocations, are further classified as simple (volar plate is not interposed in the joint) and complex (volar plate is entrapped in the joint).",
"   </p>",
"   <p>",
"    MTP dislocations are typically multiple and associated with Lisfranc fractures of the foot. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35079?source=see_link&amp;anchor=H20#H20\">",
"     \"Foot fractures (other than metatarsal or phalangeal) in children\", section on 'Tarsometatarsal (Lisfranc) fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thumb MCP dislocations are classified as follows (",
"    <a class=\"graphic graphic_figure graphicRef62404 \" href=\"UTD.htm?14/28/14784\">",
"     figure 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75156 \" href=\"UTD.htm?20/18/20783\">",
"     image 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Incomplete",
"      </strong>",
"      &ndash; Volar plate ruptured, collateral ligament intact",
"     </li>",
"     <li>",
"      <strong>",
"       Simple",
"      </strong>",
"      &ndash; Volar plate and collateral ligament ruptured",
"     </li>",
"     <li>",
"      <strong>",
"       Complex",
"      </strong>",
"      &ndash; Dislocated phalanx is entrapped in the intrinsic hand muscles and volar plate is entrapped in the joint",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PRESENTATION AND MECHANISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient with a dislocated digit has pain, swelling, loss of continuity, and impaired range of motion of the affected joint.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Interphalangeal dislocation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dorsal dislocation",
"      </strong>",
"      &ndash; Patients with dorsal joint dislocation have displacement of the distal portion of the joint toward the back of the hand or the top of the foot. Dorsal proximal interphalangeal (PIP) and distal interphalangeal (DIP) joint dislocations arise from a force that produces axial loading and hyperextension of the digit. Dorsal PIP dislocation is the most common articular injury of the hand in the skeletally mature patient. Dorsal DIP joint dislocations are frequently associated with a flexor digitorum profundus avulsion fracture called a jersey finger (",
"      <a class=\"graphic graphic_figure graphicRef53137 \" href=\"UTD.htm?22/62/23534\">",
"       figure 8",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28581?source=see_link\">",
"       \"Flexor tendon injury of the distal interphalangeal joint (jersey finger)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Volar dislocation",
"      </strong>",
"      &ndash; Volar dislocations of the PIP and DIP joints occur due to a combination of dorsal, varus (medial), and valgus (lateral) forces that rupture the collateral ligaments and the volar plate while displacing the base of the dislocated phalanx towards the palm or sole (",
"      <a class=\"graphic graphic_figure graphicRef77114 \" href=\"UTD.htm?18/14/18659\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/7\">",
"       7",
"      </a>",
"      ]. In addition, rupture of the central slip of the extensor hood complex usually occurs, and an avulsion fracture is often present [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/8\">",
"       8",
"      </a>",
"      ]. Lack of timely treatment of volar PIP finger dislocations may result in a boutonniere deformity (",
"      <a class=\"graphic graphic_figure graphicRef74107 \" href=\"UTD.htm?28/40/29327\">",
"       figure 9",
"      </a>",
"      ). Volar dislocations are rare and may be irreducible due to entrapment of the proximal phalangeal condyle between the central tendon and lateral band. Volar dislocations of the interphalangeal joint of the thumb may also present with rupture of the flexor pollicis longus tendon.",
"     </li>",
"     <li>",
"      <strong>",
"       Lateral joint dislocation",
"      </strong>",
"      &ndash; Isolated lateral dislocations of the PIP and DIP joints are rare and represent collateral ligament disruption caused by medial or lateral forces.",
"     </li>",
"     <li>",
"      <strong>",
"       Interphalangeal dislocation of the hallux (great toe)",
"      </strong>",
"      &ndash; Dislocations of the hallucal interphalangeal joint of the great toe are rare and frequently complicated by sesamoid and plantar ligament entrapment [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Metacarpophalangeal dislocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dorsal metacarpophalangeal (MCP) dislocation follows hyperextension of the affected joint with rupture of the volar plate. MCP dislocations, other than thumb dislocations, are classified as simple (no entrapment of the volar plate in the joint) or complex (interposition of the volar plate within the joint).",
"   </p>",
"   <p>",
"    Thumb MCP dislocations are caused by the same mechanisms as other digit MCP dislocations but are far more common than at the digits because of mobility of the thumb. In addition, because of the greater physiologic range of motion, these types of dislocation are more complex. They are designated as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Incomplete",
"      </strong>",
"      &ndash; Volar plate ligament disruption with some preservation of collateral ligament function",
"     </li>",
"     <li>",
"      <strong>",
"       Simple",
"      </strong>",
"      &ndash; Volar plate and collateral ligament disruption with 90 degree displacement of the thumb phalanx relative to the thumb MCP (",
"      <a class=\"graphic graphic_figure graphicRef62404 \" href=\"UTD.htm?14/28/14784\">",
"       figure 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef75156 \" href=\"UTD.htm?20/18/20783\">",
"       image 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Complex",
"      </strong>",
"      &ndash; The distal phalanx is positioned parallel to the metacarpal bone (",
"      <a class=\"graphic graphic_figure graphicRef62404 \" href=\"UTD.htm?14/28/14784\">",
"       figure 7",
"      </a>",
"      ). With these injuries, the metacarpal head may be trapped in the intrinsic muscles and the volar plate is interposed in the joint. On physical examination, puckering of skin near the affected joint suggests the possibility of volar entrapment. This finding is confirmed when plain radiographs show the sesamoid bones within the joint space [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Volar metacarpophalangeal joint dislocations are rare injuries that are typically entrapped and require operative repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Metatarsophalangeal dislocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dislocation at a single metatarsophalangeal joint frequently involves the fifth digit, which can be easily reduced. Multiple metatarsophalangeal (MTP) dislocations can be associated with Lisfranc fractures of the foot. These complex injuries require orthopedic or podiatric subspecialty care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35079?source=see_link&amp;anchor=H20#H20\">",
"     \"Foot fractures (other than metatarsal or phalangeal) in children\", section on 'Tarsometatarsal (Lisfranc) fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dislocation of the first MTP occurs rarely and should also prompt subspecialty consultation with an orthopedist or podiatrist [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/6,10\">",
"     6,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical evaluation and plain radiographs should differentiate the following injuries from digit dislocations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Open dislocations",
"      </strong>",
"      &ndash; The clinician should suspect open dislocations in patients with a wound near the dislocated joint (",
"      <a class=\"graphic graphic_picture graphicRef73162 \" href=\"UTD.htm?36/52/37700\">",
"       picture 1",
"      </a>",
"      ). These injuries require antibiotic treatment, tetanus prophylaxis, urgent orthopedic or hand surgery consultation, meticulous operative debridement, and repair of the collateral ligaments and volar plate [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Fracture-dislocations",
"      </strong>",
"      &ndash; Fracture-dislocations commonly occur in skeletally mature patients when the extended finger is struck in such a manner that longitudinal compression occurs along with hyperextension. A typical mechanism involves a ball striking the extended finger [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/12\">",
"       12",
"      </a>",
"      ]. This mechanism typically causes a fracture through the volar lip of the proximal interphalangeal (PIP) joint with dorsal displacement [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/13\">",
"       13",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In children, the growth plates are typically weaker than the surrounding ligaments. Thus, dislocations are commonly accompanied by Salter-Harris fractures because the collateral ligaments of the MCP, PIP, and DIP joints insert into the epiphyseal regions of the growth plate (",
"      <a class=\"graphic graphic_figure graphicRef79444 \" href=\"UTD.htm?26/18/26918\">",
"       figure 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef63865 \" href=\"UTD.htm?21/51/22321\">",
"       image 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Complex thumb dislocation",
"      </strong>",
"      &ndash; Volar and complex dorsal MCP joint dislocations should be evaluated and treated by a hand surgeon or orthopedist with appropriate expertise [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Metacarpophalangeal dislocation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Gamekeeper's thumb",
"      </strong>",
"      &ndash; Gamekeeper's thumb describes ulnar collateral ligament injury with lateral thumb metacarpophalangeal (MCP) instability. It is commonly seen in skiers when the ski pole forcefully abducts the thumb at the MCP joint during a fall. Physical findings include tenderness on the ulnar aspect of the thumb and a weak pinch. Valgus stress testing determines the integrity of the ulnar collateral ligament (",
"      <a class=\"graphic graphic_picture graphicRef53552 \" href=\"UTD.htm?35/14/36064\">",
"       picture 2",
"      </a>",
"      ). The diagnostic approach and treatment of gamekeeper's thumb is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32068?source=see_link&amp;anchor=H3#H3\">",
"       \"Ulnar collateral ligament injury (gamekeeper's or skier's thumb)\", section on 'Clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32068?source=see_link\">",
"       \"Ulnar collateral ligament injury (gamekeeper's or skier's thumb)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Jammed finger",
"      </strong>",
"      &ndash; \"Jammed finger\" refers to prolonged swelling of the proximal interphalangeal joint after an axial loading force (eg, basketball striking the end of an extended finger) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/14\">",
"       14",
"      </a>",
"      ]. Diagnostic criteria include lack of radiographic changes, complete functional stability of the joint, and no evidence of extensor tendon avulsion. Symptoms may arise from cartilage bruising and chondromalacia or chronic synovitis. The usual treatment for jammed finger involves therapeutic heat, passive and active range of motion exercises, and control of swelling. Aggressive, early range of motion in a supervised therapy program is useful to prevent stiffening [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/15\">",
"       15",
"      </a>",
"      ]. Occasionally, corticosteroid injection into the joint is used to reduce synovitis.",
"     </li>",
"     <li>",
"      <strong>",
"       Mallet finger",
"      </strong>",
"      &ndash; Mallet finger occurs most commonly during collision sports, such as American football and rugby, or ball-handling sports, such as basketball and baseball. The injury is usually caused by a direct blow to the tip of the finger, as when a ball strikes the fingertip or the fingertip strikes a rigid surface (",
"      <a class=\"graphic graphic_figure graphicRef66023 \" href=\"UTD.htm?14/24/14721\">",
"       figure 10",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef77830 \" href=\"UTD.htm?2/51/2879\">",
"       picture 3",
"      </a>",
"      ). The axial load from the blow causes sudden, forceful flexion of the distal phalanx. This flexion damages the extensor tendon where it attaches to the proximal portion of the distal phalanx. Less frequently, a mallet finger may occur as part of finger injuries involving lacerations or crushing mechanisms. Physical examination findings and treatment of mallet finger are discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38390?source=see_link&amp;anchor=H4#H4\">",
"       \"Extensor tendon injury of the distal interphalangeal joint (mallet finger)\", section on 'Symptoms and examination findings'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38390?source=see_link&amp;anchor=H8#H8\">",
"       \"Extensor tendon injury of the distal interphalangeal joint (mallet finger)\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician may proceed with reduction of a digit dislocation once the presence of a simple dislocation is confirmed and an open joint, associated fracture, or entrapped volar plate are excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS AND PRECAUTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should",
"    <strong>",
"     not",
"    </strong>",
"    attempt dislocation reduction prior to radiographic evaluation, especially in skeletally immature children. In addition, the clinician should defer care to the appropriate specialist (orthopedist, hand surgeon or podiatrist), if available, in patients with the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Associated digit fracture",
"     </li>",
"     <li>",
"      Open joint dislocation (",
"      <a class=\"graphic graphic_picture graphicRef73162 \" href=\"UTD.htm?36/52/37700\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Digital neurovascular compromise (unless orthopedic or hand surgery consultation is not emergently available)",
"     </li>",
"     <li>",
"      Interphalangeal joint dislocation of the great toe (hallux)",
"     </li>",
"     <li>",
"      Multiple metatarsophalangeal dislocations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prompt subspecialty consultation is also appropriate in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Volar proximal interphalangeal joint dislocation, because entrapment of the lateral band around the head of the proximal phalanx often prevents a successful closed reduction (",
"      <a class=\"graphic graphic_figure graphicRef77114 \" href=\"UTD.htm?18/14/18659\">",
"       figure 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Volar, lateral, or complex dorsal metacarpophalangeal joint dislocation, because open reduction is typically required",
"     </li>",
"     <li>",
"      Any joint dislocation with tendon rupture",
"     </li>",
"     <li>",
"      Digit dislocation that is irreducible",
"     </li>",
"     <li>",
"      Unstable joint after attempted dislocation reduction",
"     </li>",
"     <li>",
"      Patients who remain in a significant amount of discomfort after reduction for whom an occult fracture (at any age) or growth plate injury (pediatric age) is suspected",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper management of digit dislocation requires careful evaluation, including plain radiographs, prior to attempting closed reduction. This assessment should identify conditions not amenable to closed reduction or those that require prompt referral to a hand surgeon, orthopedic surgeon, or podiatrist. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Differential diagnosis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Contraindications and precautions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        History/Physical",
"       </strong>",
"      </span>",
"      examination",
"      &ndash; The clinician should obtain history and fully evaluate the site of injury prior to reduction. Key historical elements include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Age and skeletal maturity",
"     </li>",
"     <li>",
"      Mechanism and time of injury",
"     </li>",
"     <li>",
"      Digit position during injury (flexed versus extended)",
"     </li>",
"     <li>",
"      Dominant hand",
"     </li>",
"     <li>",
"      Occupation",
"     </li>",
"     <li>",
"      Prior hand conditions, injuries, or interventions",
"      <br/>",
"      <br/>",
"      Important physical examination features include:",
"     </li>",
"     <li>",
"      Site of injury (eg, maximal pain and swelling)",
"     </li>",
"     <li>",
"      Neurovascular examination, especially distal to the injury",
"     </li>",
"     <li>",
"      Presence of open wounds adjacent to the injury",
"     </li>",
"     <li>",
"      Range of motion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Radiographic studies",
"      </strong>",
"      &ndash; AP, oblique, and, most importantly, true lateral plain radiographs are necessary before the procedure to exclude associated fractures and to assist in identifying complex dislocations or other digit conditions that warrant referral to an orthopedist, hand surgeon, or podiatrist [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Contraindications and precautions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Patient",
"       <span class=\"nowrap\">",
"        counseling/Informed",
"       </span>",
"       consent",
"      </strong>",
"      &ndash; The patient with digit dislocation is typically anxious and in pain. The patient and family should receive an explanation of the problem and the procedural approach.",
"      <br/>",
"      <br/>",
"      The benefits of the joint reduction procedure usually outweigh the risks. Appropriate expectations regarding the outcome of any injury should be discussed with the patient and family. Prior to initiation of reduction attempts, the potential adverse effects of the procedure should be disclosed, including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Inadequate or delayed reduction may cause an unstable, deformed, or stiff joint",
"     </li>",
"     <li>",
"      Reduction attempts may lead to fracture",
"     </li>",
"     <li>",
"      The joint may become dislocated again if immobilization is not maintained",
"     </li>",
"     <li>",
"      Swelling of the affected joint with stiffness may be present for several months despite appropriate treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Analgesia and sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate analgesia, anesthesia, and, especially in children, distraction by a child life specialist or other personnel, may help to decrease the anxiety and pain of the procedure and promote successful reduction. A digital block often provides adequate analgesia in older adolescents and adults. In younger children, procedural sedation is frequently warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23703?source=see_link\">",
"     \"Digital nerve block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=see_link\">",
"     \"Procedural sedation in children outside of the operating room\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most instances, the clinician should provide analgesia before attempting reduction of the digit. Rarely, an older adolescent or adult with a very recent dislocation (less than one hour old) and minimal swelling may tolerate reduction without analgesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Materials",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Latex-free gloves",
"     </li>",
"     <li>",
"      1 percent buffered",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      without epinephrine (one part of 1",
"      <span class=\"nowrap\">",
"       mEq/mL",
"      </span>",
"      [8.4 percent]",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      to 9 or 10 parts of 1 percent lidocaine)",
"     </li>",
"     <li>",
"      Syringes (3 mL or 5 mL) and needles (25 or 27 gauge)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32768?source=see_link\">",
"       Povidone iodine",
"      </a>",
"      solution (eg, Betadine&trade;) and alcohol",
"     </li>",
"     <li>",
"      Scissors",
"     </li>",
"     <li>",
"      White surgical tape",
"     </li>",
"     <li>",
"      Splinting materials depend on the affected joint:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Finger interphalangeal dislocations: padded, malleable, aluminum digital splint",
"     </li>",
"     <li>",
"      Metacarpal (thumb) dislocations: water, bucket, prefabricated splinting material (eg, plaster of Paris or fiberglass)",
"      <strong>",
"       OR",
"      </strong>",
"      Webril&reg;, plaster of Paris, and stockinette to fashion a thumb spica splint (",
"      <a class=\"graphic graphic_figure graphicRef79534 \" href=\"UTD.htm?26/19/26943\">",
"       figure 11",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link&amp;anchor=H17#H17\">",
"       \"Splinting of musculoskeletal injuries\", section on 'Thumb spica splint'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Interphalangeal dislocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The procedure for proximal interphalangeal (PIP) or distal interphalangeal (DIP) dislocation reduction is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef72981 \" href=\"UTD.htm?26/30/27117\">",
"     table 1",
"    </a>",
"    ) and consists of the following steps [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/9,17\">",
"     9,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assure no fracture or open joint is present on AP, true lateral, and oblique plain radiographs.",
"     </li>",
"     <li>",
"      Remove all rings from the affected hand or foot.",
"     </li>",
"     <li>",
"      Assemble all necessary materials. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Materials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Provide appropriate analgesia as determined by the patient's age and degree of pain. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Analgesia and sedation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Interphalangeal reduction",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Have an assistant brace the hand or foot.",
"     </li>",
"     <li>",
"      Reduce the dislocation using one of the following methods:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Dorsal dislocation",
"      </strong>",
"      &ndash; Provide longitudinal traction;",
"      <strong>",
"       gently",
"      </strong>",
"      hyperextend the joint while pushing the base of the dislocated phalanx into place.",
"     </li>",
"     <li>",
"      <strong>",
"       Volar dislocation",
"      </strong>",
"      &ndash; Provide longitudinal traction;",
"      <strong>",
"       gently",
"      </strong>",
"      hyperflex while pushing the base of the dislocated phalanx into place.",
"     </li>",
"     <li>",
"      <strong>",
"       Lateral dislocation",
"      </strong>",
"      &ndash; Provide longitudinal traction;",
"      <strong>",
"       gently",
"      </strong>",
"      hyperextend the joint while correcting the ulnar or radial deformity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After reduction, test joint stability throughout the full range of motion of the digit to ensure that the joint will recover well with splinting alone [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Obtain a post-reduction plain radiograph, including a true lateral view of the digit.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Interphalangeal immobilization",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immobilize the digit based on the location and type of dislocation:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       DIP dorsal or lateral finger dislocation",
"      </strong>",
"      &ndash; Splint the DIP in full extension while allowing full range of motion of the PIP joint.",
"     </li>",
"     <li>",
"      <strong>",
"       PIP dorsal or lateral finger dislocation",
"      </strong>",
"      &ndash; Apply a dorsal splint with the PIP in 20 to 30 degrees of flexion.",
"     </li>",
"     <li>",
"      <strong>",
"       Volar finger dislocation",
"      </strong>",
"      &ndash; Splint the PIP and DIP in full extension.",
"     </li>",
"     <li>",
"      <strong>",
"       DIP or PIP toe dislocation",
"      </strong>",
"      &ndash; Buddy tape the affected digit to its neighbor (",
"      <a class=\"graphic graphic_figure graphicRef74291 \" href=\"UTD.htm?41/25/42397\">",
"       figure 12",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Simple metacarpophalangeal or metatarsophalangeal dislocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The procedure for simple metacarpophalangeal (MCP) dislocation reduction is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef72981 \" href=\"UTD.htm?26/30/27117\">",
"     table 1",
"    </a>",
"    ) and consists of the following steps [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/9,17\">",
"     9,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assure no fracture or open joint is present on AP, true lateral, and oblique plain radiographs.",
"     </li>",
"     <li>",
"      Remove all rings from the affected hand or foot.",
"     </li>",
"     <li>",
"      Assemble all necessary materials. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Materials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Provide appropriate analgesia as determined by the patient's age and degree of pain. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Analgesia and sedation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Reduction",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Have an assistant brace the hand and flex the wrist.",
"     </li>",
"     <li>",
"      Avoid excessive hyperextension or distraction that can convert a simple dislocation into a complex dislocation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gently distract the affected thumb or digit and apply volar pressure to the base of the dislocated proximal phalanx.",
"     </li>",
"     <li>",
"      Test joint stability throughout the full range of thumb motions to ensure that the joint will recover well with splinting alone [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Immobilization",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Finger dislocation",
"      </strong>",
"      &ndash; Splint the digit in 90 degrees of flexion at the MCP joint.",
"     </li>",
"     <li>",
"      <strong>",
"       Thumb dislocation",
"      </strong>",
"      &ndash; Apply a thumb spica splint with the MCP joint in 20 degrees of flexion (",
"      <a class=\"graphic graphic_figure graphicRef79534 \" href=\"UTD.htm?26/19/26943\">",
"       figure 11",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with digit dislocations should be seen within seven days to assess degree of pain, compliance with splinting, and joint stability. Unless the clinician has appropriate experience and comfort in the management of simple digit dislocations, referral to an orthopedist, hand surgeon, or podiatrist (toe dislocations) is warranted.",
"   </p>",
"   <p>",
"    Range of motion exercises should commence as soon as the splint can be removed. Duration of splinting depends on the type of dislocation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dorsal finger proximal interphalangeal (PIP)",
"      </strong>",
"      &ndash; Three to five days as needed for comfort, then buddy tape",
"     </li>",
"     <li>",
"      <strong>",
"       Dorsal finger distal interphalangeal (DIP)",
"      </strong>",
"      &ndash; Two to three weeks",
"     </li>",
"     <li>",
"      <strong>",
"       Volar PIP",
"      </strong>",
"      &ndash; Four weeks",
"     </li>",
"     <li>",
"      <strong>",
"       Simple finger metacarpophalangeal (MCP)",
"      </strong>",
"      &ndash; Three to five days",
"     </li>",
"     <li>",
"      <strong>",
"       Simple thumb MCP",
"      </strong>",
"      &ndash; Three to four weeks",
"     </li>",
"     <li>",
"      <strong>",
"       Toe dislocations",
"      </strong>",
"      &ndash; Buddy tape for two weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Return to play",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Dorsal dislocations of the PIP or DIP joint",
"      </strong>",
"      &ndash; Patients with these injuries can immediately return to play with proper splinting (finger dislocations) or buddy taping (toe dislocations) if a stable reduction is achieved, if their position does not place unusual demands on the digit (eg, quarterbacks, pitchers with an injury to the dominant hand or toe of foot used to push off), and if pain is tolerable.",
"     </li>",
"     <li>",
"      <strong>",
"       MCP joint dislocations",
"      </strong>",
"      &ndash; Patients may return to play after six to eight weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most simple digit dislocations will have full return of function as long as successful reductions are properly splinted and early range of motion occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/19\">",
"     19",
"    </a>",
"    ]. However, early referral of irreducible dislocations, avoidance of an excessive duration of splinting, and careful testing of joint stability after reduction are essential to avoid poor outcomes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Irreducible dislocations",
"      </strong>",
"      &ndash; Dislocations that are irreducible by closed reduction are uncommon, but may occur when soft tissue or bony fragments (eg, the volar plate) become interposed in the joint space [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. This is likely to be the situation if one or two attempts at reduction prove unsuccessful. These patients usually require open reduction to extract and repair the interposed ligament, tendon, or volar plate [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/5,6,10,19-23\">",
"       5,6,10,19-23",
"      </a>",
"      ]. The clinician should",
"      <strong>",
"       avoid",
"      </strong>",
"      multiple forceful attempts at reduction in these patients. Such excessive force may cause a fracture or convert a dislocation that is amenable to closed reduction to one that requires open reduction.",
"     </li>",
"     <li>",
"      <strong>",
"       Stiffness",
"      </strong>",
"      &ndash; Stiffness and joint thickening is a common complication, especially with PIP dislocations [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/22\">",
"       22",
"      </a>",
"      ]. As soon as the appropriate duration of splinting has passed, early initiation of range of motion exercises helps to decrease stiffness. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Follow-up care'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      However, in some patients, stiffness and soreness may last as long as 12 to 18 months, and result in permanent residual enlargement of the joint despite appropriate treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16216/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Recurrent dislocation",
"      </strong>",
"      &ndash; Recurrent dislocation may arise from improper splint position, inadequate duration of splinting, or inappropriate return to play. This complication is most common with metacarpophalangeal dislocations.",
"     </li>",
"     <li>",
"      <strong>",
"       Boutonniere deformity",
"      </strong>",
"      &ndash; Boutonniere deformity (hyperextension at the distal interphalangeal joint with fixed flexion at the proximal interphalangeal joint) is a potential complication in patients with volar PIP finger dislocations (",
"      <a class=\"graphic graphic_figure graphicRef74107 \" href=\"UTD.htm?28/40/29327\">",
"       figure 9",
"      </a>",
"      ). Such patients are at risk for boutonniere deformity if their dislocation is not splinted in extension or if immobilization is not maintained for at least six weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/5/33874?source=see_link\">",
"       \"Patient information: Finger dislocation (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dislocation of a digit occurs commonly among skeletally mature adolescents and active young adults. Dorsal displacement of the proximal interphalangeal joint of the finger is the most frequent dislocation. In children, digit dislocation is often associated with a growth plate fracture. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Anatomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proper management of digit dislocation requires careful evaluation, including plain radiographs, prior to attempting closed reduction. This assessment should identify conditions not amenable to closed reduction or those that require prompt referral to a hand surgeon, orthopedic surgeon, or podiatrist. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Contraindications and precautions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The type and location of digit dislocation determine the reduction technique and splinting method (",
"      <a class=\"graphic graphic_table graphicRef72981 \" href=\"UTD.htm?26/30/27117\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After reduction, careful clinical and radiographic assessment is necessary to assure complete reduction. Proper immobilization and close follow-up are essential to good outcomes. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Interphalangeal immobilization'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Immobilization'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Follow-up care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16216/abstract/1\">",
"      Leggit JC, Meko CJ. Acute finger injuries: part II. Fractures, dislocations, and thumb injuries. Am Fam Physician 2006; 73:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16216/abstract/2\">",
"      Panchal AP, Bamberger HB. Dorsal dislocation of the distal interphalangeal joint and volar dislocation of the metacarpophalangeal joint in the same finger: a case report. Hand (N Y) 2010; 5:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16216/abstract/3\">",
"      Brand PW, Cranor KC, Ellis JC. Tendon and pulleys at the metacarpophalangeal joint of a finger. J Bone Joint Surg Am 1975; 57:779.",
"     </a>",
"    </li>",
"    <li>",
"     Moore KL, Dalley AF. Clinically Oriented Anatomy, 5th, Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.705.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16216/abstract/5\">",
"      Sorene ED, Regev G. Complex dislocation with double sesamoid entrapment of the interphalangeal joint of the hallux. J Foot Ankle Surg 2006; 45:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16216/abstract/6\">",
"      Mittlmeier T, Haar P. Sesamoid and toe fractures. Injury 2004; 35 Suppl 2:SB87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16216/abstract/7\">",
"      Peimer CA, Sullivan DJ, Wild DR. Palmar dislocation of the proximal interphalangeal joint. J Hand Surg Am 1984; 9A:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16216/abstract/8\">",
"      Spinner M, Choi BY. Anterior dislocation of the proximal interphalangeal joint. A cause of rupture of the central slip of the extensor mechanism. J Bone Joint Surg Am 1970; 52:1329.",
"     </a>",
"    </li>",
"    <li>",
"     Kozin SH, Waters PM. Fractures and dislocations of the hand and carpus in children. In: Fractures in Children, 7th, Beaty JH, Kasser JR.  (Eds), Lippincott Williams &amp;  Wilkins, Philadelphia 2010. p.225.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16216/abstract/10\">",
"      Jahss MH. Traumatic dislocations of the first metatarsophalangeal joint. Foot Ankle 1980; 1:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16216/abstract/11\">",
"      Stern PJ, Lee AF. Open dorsal dislocations of the proximal interphalangeal joint. J Hand Surg Am 1985; 10:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16216/abstract/12\">",
"      Glickel SZ, Barron OA. Proximal interphalangeal joint fracture dislocations. Hand Clin 2000; 16:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16216/abstract/13\">",
"      McCue FC, Honner R, Johnson MC, Gieck JH. Athletic injuries of the proximal interphalangeal joint requiring surgical treatment. J Bone Joint Surg Am 1970; 52:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16216/abstract/14\">",
"      Benson LS, Bailie DS. Proximal interphalangeal joint injuries of the hand. Part II: Treatment and complications. Am J Orthop (Belle Mead NJ) 1996; 25:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16216/abstract/15\">",
"      Su, JK, Difiori, J. Jammed Finger. Med Sci Sports Exerc 2006; 38:S147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16216/abstract/16\">",
"      Hossfeld GE, Uehara DT. Acute joint injuries of the hand. Emerg Med Clin North Am 1993; 11:781.",
"     </a>",
"    </li>",
"    <li>",
"     Johnson FC, Okada PJ. Reduction of common joint dislocations and subluxations. In: Textbook of Pediatric Emergency Procedures, 2nd, King C, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. p.963.",
"    </li>",
"    <li>",
"     Uehara DT. Injuries of the hand and wrist. In: Pediatric Emergency Medicine: A Comprehensive Study Guide, 2nd, Strange GR, Ahrens WR, Lelyveld S, Shafemeyer RW.  (Eds), McGraw-Hill, New York 2002. p.147.",
"    </li>",
"    <li>",
"     Muelleman RL, Wadman MC. Injuries to the hand and digits. In: Emergency Medicine: A Comprehensive Study Guide, 6th, Tintinalli JE, Kelen GD, Stapczynski JS.  (Eds), McGraw-Hill, New York 2004. p.1666.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16216/abstract/20\">",
"      Ostrowski DM, Neimkin RJ. Irreducible palmar dislocation of the proximal interphalangeal joint. A case report. Orthopedics 1985; 8:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16216/abstract/21\">",
"      Itadera E. Irreducible palmar dislocation of the proximal interphalangeal joint caused by a fracture fragment: a case report. J Orthop Sci 2003; 8:872.",
"     </a>",
"    </li>",
"    <li>",
"     Simon RR, Sherman SC, Koenigsknecht SJ. Hand. In: Emergency Orthopedics: The Extremities, 5th, McGraw-Hill, New York 2007. p.123.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16216/abstract/23\">",
"      Vicar AJ. Proximal interphalangeal joint dislocations without fractures. Hand Clin 1988; 4:5.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6314 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-210.101.131.231-E769C354BE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_53_16216=[""].join("\n");
var outline_f15_53_16216=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PRESENTATION AND MECHANISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Interphalangeal dislocation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Metacarpophalangeal dislocation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Metatarsophalangeal dislocation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CONTRAINDICATIONS AND PRECAUTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Analgesia and sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Materials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Interphalangeal dislocation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Interphalangeal reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Interphalangeal immobilization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Simple metacarpophalangeal or metatarsophalangeal dislocation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Immobilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Return to play",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6314\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6314|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/28/2496\" title=\"diagnostic image 1\">",
"      Displaced PIP fx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/51/22321\" title=\"diagnostic image 2\">",
"      Finger fx dislocation child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/18/20783\" title=\"diagnostic image 3\">",
"      Thumb dislocation xray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6314|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4838\" title=\"figure 1\">",
"      Wrist hand bones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/10/4261\" title=\"figure 2\">",
"      MCP lig volar plate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/14/18659\" title=\"figure 3\">",
"      DIP PIP ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/20/2375\" title=\"figure 4\">",
"      Foot anatomy superior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/18/26918\" title=\"figure 5\">",
"      Growth plate anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/55/21361\" title=\"figure 6\">",
"      Salter-Harris classification system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/28/14784\" title=\"figure 7\">",
"      Thumb dislocation fig",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/62/23534\" title=\"figure 8\">",
"      Jersey finger",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/40/29327\" title=\"figure 9\">",
"      Boutonniere deformity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/24/14721\" title=\"figure 10\">",
"      Mallet finger mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/19/26943\" title=\"figure 11\">",
"      Thumb spica splint 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/25/42397\" title=\"figure 12\">",
"      Buddy taping",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6314|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/52/37700\" title=\"picture 1\">",
"      Open dislocation fifth PIP finger with tuft fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/14/36064\" title=\"picture 2\">",
"      Valgus stress testing thumb",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/51/2879\" title=\"picture 3\">",
"      Mallet finger photo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6314|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/30/27117\" title=\"table 1\">",
"      Digit reduction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23703?source=related_link\">",
"      Digital nerve block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42197?source=related_link\">",
"      Distal phalanx fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38390?source=related_link\">",
"      Extensor tendon injury of the distal interphalangeal joint (mallet finger)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42645?source=related_link\">",
"      Finger and thumb anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28581?source=related_link\">",
"      Flexor tendon injury of the distal interphalangeal joint (jersey finger)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35079?source=related_link\">",
"      Foot fractures (other than metatarsal or phalangeal) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/35/14903?source=related_link\">",
"      Metatarsal and toe fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40885?source=related_link\">",
"      Middle phalanx fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/5/33874?source=related_link\">",
"      Patient information: Finger dislocation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43384?source=related_link\">",
"      Procedural sedation in children outside of the operating room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20037?source=related_link\">",
"      Proximal phalanx fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=related_link\">",
"      Splinting of musculoskeletal injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44358?source=related_link\">",
"      Toe fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/20/32068?source=related_link\">",
"      Ulnar collateral ligament injury (gamekeeper's or skier's thumb)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_53_16217="Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction";
var content_f15_53_16217=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Role of antiarrhythmic drugs for ventricular arrhythmias in patients with a prior myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/53/16217/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/53/16217/contributors\">",
"     Philip J Podrid, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/53/16217/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/53/16217/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/53/16217/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/53/16217/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/53/16217/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/53/16217/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have had an acute myocardial infarction (MI) are at increased risk for sudden cardiac death (SCD), most commonly due to ventricular arrhythmias. Ventricular tachycardia (VT) and ventricular fibrillation (VF) are most common in the first hours after an MI, and the incidence then declines in phases during the days, weeks, and months after the event. However, the arrhythmic risk remains elevated for years after an MI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. This temporal pattern reflects the electrophysiologic manifestations of the evolving interactions between ischemia, infarction, reperfusion, and scar formation.",
"   </p>",
"   <p>",
"    Although all patients with a prior MI have an elevated risk of malignant arrhythmias, the magnitude of risk varies from patient to patient. Findings such as reduced left ventricular ejection fraction (LVEF), reduced heart rate variability, abnormalities in the signal averaged ECG, and T wave alternans all predict a higher likelihood of SCD. On the other hand, the risk appears to be equivalent in patients with ST elevation and non-ST elevation infarctions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to the heightened risk of malignant arrhythmias after an acute MI, antiarrhythmic drugs for the purpose of preventing SCD have been studied in two major settings: in patients with ventricular arrhythmias, and as prophylaxis.",
"   </p>",
"   <p>",
"    The role of antiarrhythmic drugs for the treatment of ventricular arrhythmias after an acute MI will be reviewed here. The pathogenesis, clinical features, and general therapy of ventricular arrhythmias after MI and of risk stratification for SCD are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12570?source=see_link\">",
"     \"Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Patients with ventricular arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular arrhythmias that occur more than 48 to 72 hours after an MI usually reflect permanent substrate for malignant arrhythmias and are associated with an increased long-term risk of SCD. The prognostic significance of arrhythmias that occur within the first 48 hours is less clear. A detailed discussion of the implications of the temporal relationship of arrhythmias to MI is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Arrhythmias that correlate with increased SCD risk include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ventricular premature beats (VPBs) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Nonsustained ventricular tachycardia (NSVT)",
"     </li>",
"     <li>",
"      Sustained VT or VF",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Due to the association of these arrhythmias with SCD, a number of trials have evaluated the utility of antiarrhythmic drugs for preventing SCD in post-MI patients with a history of ventricular arrhythmias. There are several theoretical reasons why antiarrhythmic drugs were thought to be potentially beneficial in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If nonsustained arrhythmias (ie, VPBs and NSVT) trigger malignant sustained arrhythmias, then suppressing the nonsustained arrhythmias may prevent SCD.",
"     </li>",
"     <li>",
"      If nonsustained arrhythmias are not causative, but simply reflect more diseased hearts with heightened SCD risk, they may identify high-risk subpopulations who would benefit from antiarrhythmic drug therapy.",
"     </li>",
"     <li>",
"      Patients with a history of sustained VT or VF are known to be at increased risk of recurrent events that may be prevented by antiarrhythmic medications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these theoretical benefits, trials of antiarrhythmic medications have generally shown no benefit, and in some cases have been harmful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiarrhythmic drugs have been studied as prophylaxis for SCD in post-MI patients with high-risk features other than ventricular arrhythmias (eg, reduced LVEF). As in patients with ventricular arrhythmias, antiarrhythmic drugs are not beneficial in this setting and may be harmful.",
"   </p>",
"   <p>",
"    The lack of overall mortality benefit and the potential for harm from antiarrhythmic medications must be considered in the context of the role of implantable cardioverter-defibrillators (ICDs) for both primary and secondary prevention of SCD in patients with a prior MI.",
"   </p>",
"   <p>",
"    The data supporting the limited role of antiarrhythmic drugs for the management of ventricular arrhythmias in patients with a prior MI will be reviewed here. The indications for an implantable cardioverter-defibrillator (ICD) in the management of post-MI patients, and the treatment of ventricular arrhythmias occurring in the periinfarction period are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NONSUSTAINED ARRHYTHMIAS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ventricular premature beats",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular premature beats (VPBs), particularly if frequent (more than 10 per hour) or complex, appear to be associated with a worse prognosis in patients with a prior MI. Based upon this association, trials of both class I and class III antiarrhythmic medications were conducted to determine if suppression of ventricular ectopy would reduce SCD. Detailed discussion of this topic is presented separately, and a brief review is presented here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31336?source=see_link\">",
"     \"Prophylaxis against ventricular arrhythmias following myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In CAST and CAST II, patients with ventricular ectopy post-MI were randomly assigned to receive encainide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    (both class IC antiarrhythmic agents) or moricizine [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CAST study enrolled 1498 patients with ventricular ectopy post-MI and randomly assigned them to treatment with encainide,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      , moricizine or placebo. The trial was prematurely terminated when it was noted that, despite suppression of VPBs, total mortality among the patients receiving encainide and flecainide was significantly",
"      <strong>",
"       increased",
"      </strong>",
"      compared to those on placebo (3.0 versus 7.7 percent); this was due primarily to an excess in arrhythmic deaths (",
"      <a class=\"graphic graphic_figure graphicRef59975 \" href=\"UTD.htm?19/4/19534\">",
"       figure 1",
"      </a>",
"      ). As a result, encainide was withdrawn from the market and flecainide is not used in patients with coronary heart disease.",
"     </li>",
"     <li>",
"      CAST II enrolled 1325 patients, but limited treatment to moricizine or placebo. This trial was also terminated early due to an increased risk death or cardiac arrest in the first 14 days of therapy among patients treated with moricizine (2.6 versus 0.5 percent with placebo) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/8\">",
"       8",
"      </a>",
"      ]. Thus, this agent is not recommended in this population.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CAMIAT evaluated 1202 post-MI patients with frequent (&ge;10 per hour) or repetitive VPBs. The patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    or placebo, and approximately 60 percent were also treated with a beta blocker [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/9\">",
"     9",
"    </a>",
"    ]. The following were the major findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arrhythmia suppression was more common with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      (84 versus 35 percent with placebo).",
"     </li>",
"     <li>",
"      There was no significant difference in yearly all-cause or cardiac mortality (4.0 versus 5.2 percent, p = 0.11).",
"     </li>",
"     <li>",
"      The yearly rate of arrhythmic death or resuscitated ventricular fibrillation was significantly lower in the patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , whether intention-to-treat (2.3 versus 3.7 percent) or efficacy analysis (1.8 versus 3.4 percent) was performed (",
"      <a class=\"graphic graphic_figure graphicRef67684 \" href=\"UTD.htm?26/38/27246\">",
"       figure 2",
"      </a>",
"      ). The antiarrhythmic benefit was greatest in patients with heart failure (HF).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no role for chronic antiarrhythmic drug therapy to suppress asymptomatic VPBs. In the postinfarction patient with VPBs that cause significant or disabling symptoms (eg, palpitations, lightheadedness), beta-blockers are recommended, although most patients will already be taking them. In the rare circumstance that more aggressive antiarrhythmic therapy is considered for control of refractory symptoms, we recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , as it is likely to be effective and unlikely to cause significant harm, although there is an appreciable incidence of side effects with long-term amiodarone therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nonsustained VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of NSVT one week or later post-MI carries at least a two-fold increase in the risk of SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/10\">",
"     10",
"    </a>",
"    ]. The risk of NSVT is even further increased in post-MI patients with significantly diminished left ventricular function (left ventricular ejection fraction less than 40 percent). In this setting, the risk of SCD is increased more than five-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. NSVT that is first detected more than one year post-MI carries a two-fold increase in the risk of SCD, particularly when associated with clinical evidence of left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39702?source=see_link&amp;anchor=H4#H4\">",
"     \"Prognosis of nonsustained VT in the presence of structural heart disease\", section on 'Coronary heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Large randomized trials of antiarrhythmic drugs limited to patients with NSVT have not been performed. However, many of the patients included in the CAST and CAMIAT (39 percent) trials had NSVT. As described above, these trials showed an increased mortality in patients treated with class IC antiarrhythmic medications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/7\">",
"     7",
"    </a>",
"    ], and no significant reduction in overall mortality with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With regard to risk stratification, NSVT was an inclusion criteria in the MUSTT and MADIT-I trials of primary prevention with an ICD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. However, the significance of NSVT in risk stratification has become less prominent due to poor sensitivity, specificity, and reproducibility, combined with the evolution of broader ICD indications based upon LVEF and HF alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of data specific to patients with NSVT, we do not recommend chronic antiarrhythmic drug therapy to suppress asymptomatic NSVT.",
"   </p>",
"   <p>",
"    For patients with symptomatic (eg, palpitations, lightheadedness) NSVT after an MI, beta-blockers are recommended, although most patients should already be taking them. If antiarrhythmic drug therapy is considered due to persistent symptoms, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , as it is likely to be effective and unlikely to cause significant harm, although there is an appreciable incidence of side effects with long-term amiodarone therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of NSVT in post-MI patients with an LVEF &le;40 percent is an indication for further risk stratification, if the patient does not already meet criteria for ICD placement (LVEF &le;30 or LVEF&le;35 with NYHA class II or III HF). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUSTAINED ARRHYTHMIAS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Accelerated idioventricular rhythm",
"    </span>",
"    &nbsp;&mdash;&nbsp;An accelerated idioventricular rhythm (AIVR), which has also been called \"slow VT,\" arises below the atrioventricular node and has, by definition, a rate between 50 and 100 or 120",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    (",
"    <a class=\"graphic graphic_waveform graphicRef52385 \" href=\"UTD.htm?39/57/40856\">",
"     waveform 1",
"    </a>",
"    ). It may result from pacemaker failure, and therefore be an escape rhythm, or it may represent an abnormal ectopic focus in the ventricle that is accelerated by sympathetic stimulation and circulating catecholamines.",
"   </p>",
"   <p>",
"    AIVR is most often seen in the periinfarction period. Some studies have suggested an association with reperfusion following thrombolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/15\">",
"     15",
"    </a>",
"    ]. However, AIVR is neither a sensitive nor very specific marker for successful reperfusion.",
"   </p>",
"   <p>",
"    Most episodes are transient, benign, and require no treatment. Furthermore, pharmacologic therapy is contraindicated if AIVR is an escape rhythm, since suppression of the pacemaker focus can result in profound bradycardia and possibly asystole. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\", section on 'Accelerated idioventricular rhythm'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AIVR occurring after the periinfarction period is uncommon. When it occurs, reversible causes should be sought such as digitalis toxicity, hypokalemia, or hypomagnesemia. There are no convincing data linking AIVR to sustained VT, VF, or a worse prognosis. Thus, no therapy is warranted for asymptomatic arrhythmias, while symptomatic arrhythmias can be treated with antiarrhythmic drugs or perhaps ablation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Sustained monomorphic VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to sustained monomorphic ventricular tachycardia (SMVT) in patients with a prior MI period are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=see_link\">",
"     \"Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\", section on 'Sustained ventricular tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly, SMVT that occurs more than 48 to 72 hours after an MI is clearly associated with an increased mortality risk compared to patients without this arrhythmia. SMVT that occurs in the earlier periinfarction predicts short term mortality, and, in contrast to early VF, may also predict long term arrhythmic risk [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, even when drug selection is guided by electrophysiology studies, antiarrhythmic drugs alone have limited efficacy for preventing SMVT. For this reason, the present role of antiarrhythmic drugs in patients with SMVT is typically as an adjunct to an ICD to suppress recurrent arrhythmia.",
"   </p>",
"   <p>",
"    Available data suggest that the class III drugs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ) are more effective than the class I drugs for the treatment of SMVT and are the preferred agents when antiarrhythmic drugs are used. Sotalol and amiodarone appear to be equally effective but, due to the negative inotropic properties of sotalol, amiodarone is preferred in patients with left ventricular dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Polymorphic VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymorphic VT associated with a normal QT interval is an uncommon arrhythmia following an acute MI (",
"    <a class=\"graphic graphic_waveform graphicRef54538 \" href=\"UTD.htm?7/6/7271\">",
"     waveform 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef67322 \" href=\"UTD.htm?31/19/32054\">",
"     waveform 3",
"    </a>",
"    ). When it occurs, it is often associated with signs or symptoms of recurrent myocardial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/17\">",
"     17",
"    </a>",
"    ]. This type of polymorphic VT generally fails to respond to class I antiarrhythmic drugs, magnesium, or overdrive pacing, but may respond to intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/17\">",
"     17",
"    </a>",
"    ]. An intraaortic balloon pump may help stabilize these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=see_link&amp;anchor=H14#H14\">",
"     \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\", section on 'Polymorphic VT in coronary heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Revascularization has traditionally been considered to be adequate therapy for polymorphic VT due to ischemia in the absence of acute MI. However, more recent data suggest that ICD implantation in addition to revascularization may be optimal [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a second form of polymorphic VT that develops during the healing phase (at 3 to 11 days) and occurs in association with QT prolongation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/19\">",
"     19",
"    </a>",
"    ]. This arrhythmia resembles an acquired long QT syndrome and is treated in a similar fashion. One report of eight such patients found that defibrillation (if the arrhythmia is sustained), magnesium,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    , beta blockers, and rapid overdrive pacing were effective therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/19\">",
"     19",
"    </a>",
"    ]. In general, the QT interval shortened within 10 days and long-term outcomes were uneventful.",
"   </p>",
"   <p>",
"    More commonly, polymorphic VT is torsades de pointes, resulting from acquired long QT syndrome induced by class III antiarrhythmic drugs or other agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Ventricular fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early occurrence (within 24 to 48 hours) of primary VF among patients with an acute MI is associated with an increase in in-hospital mortality, but no increase in mortality during short-term follow-up (one to two years) among 30-day survivors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link&amp;anchor=H24#H24\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\", section on 'Ventricular fibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Later VF, at two to three weeks, appears to result from progressive pump dysfunction. Risk factors include an anterior MI with right bundle branch block and an LVEF &le;35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple clinical trials have shown that in other settings, including patients with underlying coronary heart disease, an ICD improves survival compared to antiarrhythmic drug therapy, usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , in survivors of sudden cardiac death. Amiodarone therapy may be used in such patients to reduce recurrent arrhythmias that trigger appropriate ICD discharges",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to suppress recurrences of atrial fibrillation. In addition, amiodarone should be considered as a primary therapy in patients who are not candidates for or do not wish to have an ICD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link&amp;anchor=H12#H12\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\", section on 'Adjunctive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, evidence does not support the use of antiarrhythmic medications for overall mortality reduction in patients with ventricular arrhythmias post-MI. Antiarrhythmic medications have also been evaluated as SCD prophylaxis in patients without demonstrable ventricular arrhythmias, but with other features that put them at high risk for SCD. Medications studied in this setting include beta blockers and class III antiarrhythmics (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    , azimilide, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers improve survival in patients who have had an MI in part by reducing the incidence of SCD (",
"    <a class=\"graphic graphic_figure graphicRef80761 \" href=\"UTD.htm?23/13/23774\">",
"     figure 3",
"    </a>",
"    ). In a systematic review, the overall mortality in 31 long-term trials that included almost 25,000 patients was 9.7 percent; beta blockers reduced the odds of death by 23 percent (95% CI 15 to 31 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/21\">",
"     21",
"    </a>",
"    ]. These benefits are seen following both ST elevation (Q wave) and non-ST elevation (non-Q wave) MIs (",
"    <a class=\"graphic graphic_figure graphicRef79592 \" href=\"UTD.htm?16/50/17198\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/22\">",
"     22",
"    </a>",
"    ]. The efficacy of beta blockers persists in patients treated with certain other antiarrhythmic drugs, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    and the class I antiarrhythmic drugs (",
"    <a class=\"graphic graphic_figure graphicRef68950 graphicRef55671 \" href=\"UTD.htm?26/49/27423\">",
"     figure 5A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. A detailed discussion of the role of beta blockers in patients with a prior MI is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=see_link\">",
"     \"Beta blockers in the management of acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Amiodarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    has multiple actions including beta blockade. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=see_link\">",
"     \"Clinical uses of amiodarone\"",
"    </a>",
"    .) The possible efficacy of amiodarone in post-MI patients with ventricular ectopy was evaluated in the CAMIAT and MUSTT trials [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/9,13\">",
"     9,13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Ventricular premature beats'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The possible efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    as prophylactic therapy in broader populations in which not all patients had ventricular ectopy was evaluated in the EMIAT and SCD-HeFT trials. In EMIAT, almost 1500 patients with a recent MI and an LVEF below 40 percent were randomly assigned to treatment with amiodarone or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/25\">",
"     25",
"    </a>",
"    ]. At two years, the following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      therapy was associated with a significant reduction in arrhythmic deaths plus arrhythmias requiring resuscitation (relative risk 0.68) (",
"      <a class=\"graphic graphic_figure graphicRef82573 \" href=\"UTD.htm?1/35/1599\">",
"       figure 6",
"      </a>",
"      ), although amiodarone did not reduce total or cardiac mortality.",
"     </li>",
"     <li>",
"      In subset analysis,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      reduced total mortality in patients with an ejection fraction &lt;30 percent, with VPBs on the initial Holter, with concurrent beta blocker therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/26\">",
"       26",
"      </a>",
"      ], or reduced HRV [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/27\">",
"       27",
"      </a>",
"      ]. In contrast, there was a trend toward an increase in total mortality in patients without these features. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/22/10601?source=see_link\">",
"       \"Heart rate variability: Use after myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In SCD-HeFT, 2521 patients with an LVEF &le;35 percent and NYHA class II or III HF were randomly assigned to placebo,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , or an ICD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/28\">",
"     28",
"    </a>",
"    ]. Amiodarone did not reduce mortality compared to placebo in this population. In contrast to EMIAT, subset analysis in SCD-HeFT did not show mortality reduction with amiodarone in any subgroup.",
"   </p>",
"   <p>",
"    Thus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    alone does not reduce overall mortality in most patients at increased risk for SCD, with the possible exception of selected post-MI patients. Even in such patients, however, the benefits of an ICD are greater.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     In combination with beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of the combination of beta blockers and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    was evaluated in a pooled analysis of EMIAT and CAMIAT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/23\">",
"     23",
"    </a>",
"    ]. Inclusion criteria for these two studies was slightly different, as CAMIAT enrolled patients with ventricular ectopy and EMIAT enrolled patients with a reduced LVEF. Amiodarone alone did not reduce total mortality in either study, but in the pooled analysis, amiodarone in combination with beta blockers significantly reduced both nonarrhythmic and arrhythmic cardiac death (",
"    <a class=\"graphic graphic_figure graphicRef68950 graphicRef55671 \" href=\"UTD.htm?26/49/27423\">",
"     figure 5A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Dofetilide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    was evaluated in the DIAMOND-MI trial, which enrolled 1510 patients with an acute Ml and a left ventricular ejection fraction &le;35 percent; patients were randomly assigned to dofetilide (0.5 mg twice per day) or placebo within seven days of the MI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/29\">",
"     29",
"    </a>",
"    ]. The one year mortality was 31 percent, and the incidence of arrhythmic death was 17 percent. Total mortality, cardiac mortality, arrhythmic mortality, and the combined end point of cardiac death and resuscitation were the same in both groups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28663?source=see_link\">",
"     \"Therapeutic use of dofetilide\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Azimilide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prophylactic use of azimilide, which is still investigational, was evaluated in the ALIVE trial of 3717 patients with a recent MI (5 to 21 days) who had a left ventricular ejection fraction of 15 to 35 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/30\">",
"     30",
"    </a>",
"    ]. There was no assessment of the effect of the drug on ventricular arrhythmias. After a one year follow-up, the mortality with azimilide (100 mg daily) and placebo were identical (12 percent). Azimilide also failed to reduce mortality in a subset with low heart rate variability.",
"   </p>",
"   <p>",
"    In another trial specifically evaluating ventricular arrhythmias, the benefit of azimilide was compared to placebo in 172 patients with an ICD; approximately 80 percent had had a previous MI that had occurred more than 90 days prior to randomization [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/31\">",
"     31",
"    </a>",
"    ]. At a mean follow-up of nine months, the incidence of appropriate ICD therapies was significantly reduced by azimilide (10 versus 36 per patient-year with placebo).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Sotalol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     Sotalol",
"    </a>",
"    is a racemic mixture of d and l isomers; both isomers have similar class III antiarrhythmic effects, while the l-isomer is responsible for virtually all of the beta blocking activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=see_link\">",
"     \"Therapeutic use and major side effects of sotalol\"",
"    </a>",
"    .),",
"   </p>",
"   <p>",
"    An initial controlled trial evaluated d,l-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    in 1456 patients 5 to 14 days post-MI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/32\">",
"     32",
"    </a>",
"    ]. At one year, an 18 percent reduction in mortality was noted (7.3 versus 8.9 percent), a change that was not statistically significant due perhaps to the small number of patients studied and the brief duration of follow-up.",
"   </p>",
"   <p>",
"    The efficacy of d-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , which is devoid of beta blocking activity, was evaluated in the SWORD trial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/33\">",
"     33",
"    </a>",
"    ]. This trial randomly assigned patients with an LVEF &le;40 percent and either a recent MI or symptomatic heart failure and a remote MI to d-sotalol or placebo. The trial was stopped after less than one-half of the planned 6400 patients were enrolled because of a significant",
"    <strong>",
"     increase",
"    </strong>",
"    in mortality in the d-sotalol group (5.0 versus 3.1 percent) that was largely due to an increase in presumed arrhythmic deaths (3.6 versus 2.0 percent) (",
"    <a class=\"graphic graphic_figure graphicRef71934 \" href=\"UTD.htm?33/24/34189\">",
"     figure 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Most of the increase in mortality occurred in patients with a remote MI and an LVEF of 31 to 40 percent, not in those with a recent MI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/34\">",
"     34",
"    </a>",
"    ]. There was little objective data supporting torsades de pointes or any specific proarrhythmic mechanism as an explanation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These two studies showed a mortality benefit for an unselected post-MI population with d,l-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    , but increased mortality in patients with a reduced LVEF given d-sotalol. It is not known whether these differences are due to differences in patient populations, the beneficial effect of beta-blockade with d,l-sotalol or increased proarrhythmic effects with d-sotalol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Heart failure therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not considered antiarrhythmic drugs, ACE inhibitors, aldosterone antagonists, and angiotensin II receptor blockers all reduce the incidence of SCD in patients with HF. Reduced SCD rates have been reported specifically in post-MI populations with ACE inhibitors and aldosterone antagonists, and in a broader population of HF patients, approximately 50 percent of whom had a prior infarction, with an ARB. These topics are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=see_link&amp;anchor=H14#H14\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials\", section on 'Effect on sudden death'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2680?source=see_link\">",
"     \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=see_link&amp;anchor=H4#H4\">",
"     \"Use of aldosterone antagonists in heart failure\", section on 'Eplerenone in EPHESUS trial'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/51/27442?source=see_link\">",
"       \"Patient information: Ventricular tachycardia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, only beta blockers are recommended for the primary prevention of SCD in post-MI patients. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Beta blockers'",
"    </a>",
"    above.) Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    reduces arrhythmic death, it did not reduce overall mortality in either EMIAT or CAMIAT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16217/abstract/9,25\">",
"     9,25",
"    </a>",
"    ]. Another concern, in the absence of clear evidence of benefit, is the appreciable incidence of side effects with long-term amiodarone therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At present, there are only three common indications for antiarrhythmic drug therapy for the treatment of ventricular arrhythmias in patients who have had a prior MI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rare patients with intolerable symptoms from otherwise benign nonsustained arrhythmias, that cannot be controlled with beta blockers. Due to the absence of mortality benefit and the potential for harm (proarrhythmic effects and side effects), this approach should be reserved for patients with severe and persistent symptoms.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      or less often",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      as adjunctive therapy to control ventricular arrhythmias and reduce the frequency of ICD shocks in patients with an ICD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link\">",
"       \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      , usually in combination with a beta blocker, in patients with potentially life-threatening ventricular arrhythmias who do not want or are not candidates for an ICD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=see_link\">",
"       \"Pharmacologic therapy in survivors of sudden cardiac arrest\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/1\">",
"      Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/2\">",
"      Torp-Pedersen C, K&oslash;ber L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 1999; 354:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/3\">",
"      Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005; 352:2581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/4\">",
"      Yap YG, Duong T, Bland M, et al. Temporal trends on the risk of arrhythmic vs. non-arrhythmic deaths in high-risk patients after myocardial infarction: a combined analysis from multicentre trials. Eur Heart J 2005; 26:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/5\">",
"      Berger CJ, Murabito JM, Evans JC, et al. Prognosis after first myocardial infarction. Comparison of Q-wave and non-Q-wave myocardial infarction in the Framingham Heart Study. JAMA 1992; 268:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/6\">",
"      Maggioni AP, Zuanetti G, Franzosi MG, et al. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI-2 results. Circulation 1993; 87:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/7\">",
"      Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/8\">",
"      Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med 1992; 327:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/9\">",
"      Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 1997; 349:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/10\">",
"      Bigger JT Jr, Fleiss JL, Rolnitzky LM. Prevalence, characteristics and significance of ventricular tachycardia detected by 24-hour continuous electrocardiographic recordings in the late hospital phase of acute myocardial infarction. Am J Cardiol 1986; 58:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/11\">",
"      Mukharji J, Rude RE, Poole WK, et al. Risk factors for sudden death after acute myocardial infarction: two-year follow-up. Am J Cardiol 1984; 54:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/12\">",
"      Buxton AE, Marchlinski FE, Waxman HL, et al. Prognostic factors in nonsustained ventricular tachycardia. Am J Cardiol 1984; 53:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/13\">",
"      Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/14\">",
"      Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/15\">",
"      Gorgels AP, Vos MA, Letsch IS, et al. Usefulness of the accelerated idioventricular rhythm as a marker for myocardial necrosis and reperfusion during thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1988; 61:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/16\">",
"      Newby KH, Thompson T, Stebbins A, et al. Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators. Circulation 1998; 98:2567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/17\">",
"      Wolfe CL, Nibley C, Bhandari A, et al. Polymorphous ventricular tachycardia associated with acute myocardial infarction. Circulation 1991; 84:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/18\">",
"      Natale A, Sra J, Axtell K, et al. Ventricular fibrillation and polymorphic ventricular tachycardia with critical coronary artery stenosis: does bypass surgery suffice? J Cardiovasc Electrophysiol 1994; 5:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/19\">",
"      Halkin A, Roth A, Lurie I, et al. Pause-dependent torsade de pointes following acute myocardial infarction: a variant of the acquired long QT syndrome. J Am Coll Cardiol 2001; 38:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/20\">",
"      Zimetbaum PJ, Josephson ME. Use of the electrocardiogram in acute myocardial infarction. N Engl J Med 2003; 348:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/21\">",
"      Freemantle N, Cleland J, Young P, et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/22\">",
"      Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/23\">",
"      Boutitie F, Boissel JP, Connolly SJ, et al. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circulation 1999; 99:2268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/24\">",
"      Kennedy HL, Brooks MM, Barker AH, et al. Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. Am J Cardiol 1994; 74:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/25\">",
"      Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997; 349:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/26\">",
"      Janse MJ, Malik M, Camm AJ, et al. Identification of post acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone. A substudy of EMIAT (the European Myocardial Infarct Amiodarone Trial). Eur Heart J 1998; 19:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/27\">",
"      Malik M, Camm AJ, Janse MJ, et al. Depressed heart rate variability identifies postinfarction patients who might benefit from prophylactic treatment with amiodarone: a substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial). J Am Coll Cardiol 2000; 35:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/28\">",
"      Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/29\">",
"      K&oslash;ber L, Bloch Thomsen PE, M&oslash;ller M, et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet 2000; 356:2052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/30\">",
"      Camm AJ, Pratt CM, Schwartz PJ, et al. Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation 2004; 109:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/31\">",
"      Singer I, Al-Khalidi H, Niazi I, et al. Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators. J Am Coll Cardiol 2004; 43:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/32\">",
"      Julian DG, Prescott RJ, Jackson FS, Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982; 1:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/33\">",
"      Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996; 348:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16217/abstract/34\">",
"      Pratt CM, Camm AJ, Cooper W, et al. Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die? Am J Cardiol 1998; 81:869.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 61 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-14B9D587E9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_53_16217=[""].join("\n");
var outline_f15_53_16217=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Patients with ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NONSUSTAINED ARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nonsustained VT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUSTAINED ARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Accelerated idioventricular rhythm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Sustained monomorphic VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Polymorphic VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Ventricular fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Amiodarone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - In combination with beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Dofetilide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Azimilide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Sotalol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Heart failure therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/61\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/61|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/4/19534\" title=\"figure 1\">",
"      Proarrhythmia with class Ic antiarrhythmic drugs in CAST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/38/27246\" title=\"figure 2\">",
"      Amiodarone in CAMIAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/13/23774\" title=\"figure 3\">",
"      Propranolol after acute MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/50/17198\" title=\"figure 4\">",
"      Beta blocker Q wave NQWMI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/31/17918\" title=\"figure 5A\">",
"      Outcome beta blocker amiodarone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/49/41757\" title=\"figure 5B\">",
"      Mortality beta blocker amio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/35/1599\" title=\"figure 6\">",
"      Amiodarone in EMIAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/24/34189\" title=\"figure 7\">",
"      Sotalol after MI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/61|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?39/57/40856\" title=\"waveform 1\">",
"      ECG Accelerated idioventricular rhythm tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?7/6/7271\" title=\"waveform 2\">",
"      ECG_1 Polymorphic VT in ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?31/19/32054\" title=\"waveform 3\">",
"      ECG_2 Polymorphic VT in ischemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2680?source=related_link\">",
"      Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=related_link\">",
"      Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=related_link\">",
"      Clinical uses of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/22/10601?source=related_link\">",
"      Heart rate variability: Use after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=related_link\">",
"      Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12570?source=related_link\">",
"      Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/51/27442?source=related_link\">",
"      Patient information: Ventricular tachycardia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=related_link\">",
"      Pharmacologic therapy in survivors of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39702?source=related_link\">",
"      Prognosis of nonsustained VT in the presence of structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31336?source=related_link\">",
"      Prophylaxis against ventricular arrhythmias following myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29193?source=related_link\">",
"      Sustained monomorphic ventricular tachycardia in patients with a prior myocardial infarction: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=related_link\">",
"      Therapeutic use and major side effects of sotalol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28663?source=related_link\">",
"      Therapeutic use of dofetilide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_53_16218="Preparations for postmenopausal hormone therapy";
var content_f15_53_16218=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Preparations for postmenopausal hormone therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/53/16218/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/53/16218/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/53/16218/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/53/16218/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/53/16218/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/53/16218/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/53/16218/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/53/16218/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/53/16218/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen therapy in postmenopausal women relieves menopausal symptoms, but has risks for some women, including breast cancer, coronary heart disease, stroke, and venous thromboembolism. For most peri- and postmenopausal women with clinically significant menopausal symptoms, postmenopausal hormone therapy (HT) is still a good option when used at low doses for a short period of time. This topic will review the available estrogen and progestin preparations. Other aspects of menopausal symptoms and hormone therapy are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=see_link\">",
"     \"Treatment of menopausal symptoms with hormone therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=see_link\">",
"     \"Menopausal hot flashes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=see_link\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=see_link\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ESTROGEN PREPARATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a decision has been made to treat a postmenopausal woman with estrogen, consideration should be given to the type of estrogen and the route by which it is to be given, as well as the need for progestin and the most appropriate progestin regimen. Estrogen is available in many forms: oral, transdermal, topical gels and lotions, intravaginal creams and tablets, and vaginal rings. In some countries, estrogen can also be given as a subcutaneous implant (",
"    <a class=\"graphic graphic_table graphicRef78136 \" href=\"UTD.htm?18/49/19230\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Systemic estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic estrogen is most often administered orally or transdermally (",
"    <a class=\"graphic graphic_table graphicRef78136 \" href=\"UTD.htm?18/49/19230\">",
"     table 1",
"    </a>",
"    ). There are several important differences in the effects of these preparations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Estrogen administered orally has a greater effect on the liver due to the first-pass effect, because intestinal absorption leads to portal vein concentrations that are initially substantially higher than those after transdermal administration. Thus, oral estrogen administration increases hepatic production of thyroxine-binding globulin, corticosteroid-binding globulin, sex hormone-binding globulin, triglycerides, high-density lipoprotein (HDL) cholesterol, and clotting factors, whereas their production is only minimally increased by transdermal estrogen administration [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Furthermore, the saturation of bile with cholesterol is adversely affected by oral, but not transdermal, estrogen [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/4\">",
"       4",
"      </a>",
"      ]. Thus, transdermal estrogen is preferred in those women in whom it is important to minimize these effects. All of the progestin regimens described below are effective for the prevention of endometrial cancer, whether oral or transdermal estrogen is used [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transdermal estrogen is as effective as oral estrogen in preserving bone density (",
"      <a class=\"graphic graphic_figure graphicRef51848 \" href=\"UTD.htm?38/11/39101\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/6\">",
"       6",
"      </a>",
"      ] and in treating menopausal symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/7\">",
"       7",
"      </a>",
"      ]. Transdermal estrogen administration is associated with a lower risk of venous thrombosis and stroke, and has less of an effect on serum lipid concentrations when compared with a comparable dose of oral estrogen [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/2,3,8\">",
"       2,3,8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=see_link&amp;anchor=H27#H27\">",
"       \"Postmenopausal hormone therapy and cardiovascular risk\", section on 'Lipids'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=see_link&amp;anchor=H18#H18\">",
"       \"Postmenopausal hormone therapy and cardiovascular risk\", section on 'Venous thromboembolism'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The different oral estrogens have similar efficacy. Conjugated equine estrogen and estrone sulfate are absorbed from the gastrointestinal tract primarily as estrone sulfate, which is biologically inactive. Oral estradiol is converted to estrone and then estrone sulfate in liver and other tissues. In women taking oral estradiol, circulating estrone sulfate accumulates as a large precursor pool. The estrone sulfate is then continuously desulfated and converted to estradiol. Therefore, even though oral estrogen is administered in a single daily dose, the resulting serum estradiol concentrations vary little between doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Oral estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many oral preparations of estrogen are available. A commonly used preparation has been a mixture of sulfoconjugated equine estrogens (Premarin), which is derived from pregnant mares' urine. In order for estrogens to appear in the urine, they must undergo conjugation to become polar and soluble in water. The same applies to absorption; unconjugated estrogens (and progestins) are poorly absorbed. Oral estradiol is poorly absorbed unless it is micronized, in which case it is absorbed through the lymphatic system in the process by which fats are absorbed.",
"   </p>",
"   <p>",
"    Most of the other oral estrogen preparations are derived from plant sources (soy and yams). There is no evidence that plant-derived estrogens have safety and efficacy advantages over those derived from pregnant mare urine. However, in our experience, many women prefer the plant-derived estrogens.",
"   </p>",
"   <p>",
"    A number of oral estrogen preparations are available (",
"    <a class=\"graphic graphic_table graphicRef78136 \" href=\"UTD.htm?18/49/19230\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/23/35184?source=see_link\">",
"       Conjugated equine estrogens",
"      </a>",
"      are comprised mostly of estrone sulfate, with small amounts of equilin sulfate, dihydroequilin sulfate, and many other estrogens [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/1\">",
"       1",
"      </a>",
"      ]. Synthetic conjugated estrogens are available that are derived from a plant source; they are similar but not identical to conjugated equine estrogens, as they contain fewer forms of estrogen.",
"     </li>",
"     <li>",
"      Oral micronized estradiol.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/39/29303?source=see_link\">",
"       Esterified estrogens",
"      </a>",
"      result in serum estradiol and estrone levels that are comparable to those seen with conjugated equine estrogen [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Estrone sulfate, ethinyl estradiol, the estrogen used in all oral contraceptive preparations. This is much more potent and, therefore, is used in very low doses (5 mcg).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The potency and, therefore, the doses of these estrogen preparations differ, but they differ little in efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/10\">",
"     10",
"    </a>",
"    ]. In general, 0.625 mg of conjugated estrogens,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/39/29303?source=see_link\">",
"     esterified estrogens",
"    </a>",
"    , or estrone sulfate is considered equivalent to 1 mg of micronized estradiol, 0.05 mg of transdermal estradiol, or 5 mcg of ethinyl estradiol. (The latter is an extremely potent synthetic estrogen that is used in oral contraceptive preparations but less often for hormone therapy [although it is used in at least one combined estrogen-progestin product, Femhrt, which contains 2.5 to 5 mcg of ethinyl estradiol with 0.5 or 1 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone acetate",
"    </a>",
"    , respectively] (",
"    <a class=\"graphic graphic_table graphicRef78136 \" href=\"UTD.htm?18/49/19230\">",
"     table 1",
"    </a>",
"    )).",
"   </p>",
"   <p>",
"    These doses protect bone, but occasionally do not completely ameliorate menopausal symptoms, particularly in women who have undergone bilateral oophorectomy. Lower doses are effective for vasomotor symptoms in some women, and there is a current trend to start with lower doses and titrate up to treat symptoms as needed. (See",
"    <a class=\"local\" href=\"#H533431036\">",
"     'Low-dose estrogen'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For women post-oophorectomy, it is sometimes necessary to start with higher doses for symptomatic relief (for example, oral estradiol 1 mg or higher if needed), but the dose should then be reduced. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of menopausal symptoms with hormone therapy\", section on 'Dose'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Combined estrogen-progestin preparations are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Transdermal estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many transdermal estrogen preparations available that contain 17-beta estradiol. There is a wide range of dosing options, from 25 mcg to 100",
"    <span class=\"nowrap\">",
"     mcg/day.",
"    </span>",
"    A transdermal dose of 50",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/6\">",
"     6",
"    </a>",
"    ] is approximately equivalent to a 0.625 mg daily oral dose of conjugated estrogens [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An even lower dose patch containing 0.014 mg of estradiol is approved for prevention of osteoporosis. In some women, the dose is adequate for hot flash relief [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. For women with a uterus, addition of a progestin is recommended, although the optimal interval for its administration is not known. Many clinicians administer one or two 14-day cycles of oral progestin per year, although this has not been well studied.",
"   </p>",
"   <p>",
"    Combination patches are also available. One contains 17-beta estradiol (0.05",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone acetate",
"    </a>",
"    (0.14 or 0.25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    applied twice weekly). This preparation appears to be comparable to other combined regimens for relief of vasomotor flushes and prevention of endometrial hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/13\">",
"     13",
"    </a>",
"    ]. A second combination patch contains 17-beta estradiol (0.045",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    (0.15",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    and is applied once a week (",
"    <a class=\"graphic graphic_table graphicRef78136 \" href=\"UTD.htm?18/49/19230\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H533430863\">",
"    <span class=\"h3\">",
"     Topical estradiol",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of topical estradiol preparations are commercially available. All are effective for the treatment of vasomotor symptoms. The preparations available in the US include the following (",
"    <a class=\"graphic graphic_table graphicRef78136 \" href=\"UTD.htm?18/49/19230\">",
"     table 1",
"    </a>",
"    ):",
"    <br/>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Estrasorb is a white lotion-like emulsion that is applied to the thighs or calves of each leg (foil packets, one packet per leg, total dose of 3.48",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      which delivers 0.05 mg",
"      <span class=\"nowrap\">",
"       estradiol/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are several gels available:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      EstroGel is packaged in a non-aerosol, metered-dose pump, and is applied once daily on one arm (from wrist to shoulder). The recommended daily dose is 1.25 g which delivers 0.75 mg",
"      <span class=\"nowrap\">",
"       estradiol/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/15\">",
"       15",
"      </a>",
"      ]. In one trial of 221 postmenopausal women with vasomotor flushes, a significant decrease in the frequency of flushes was seen with this dose when compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Divigel is supplied in foil packets and is available in three doses: 0.25, 0.50, and 1.0 mg of estradiol [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Elestrin is administered via a pump in two doses (0.87 g which contains 0.52 mg of estradiol and 1.7 g, which contains approximately 1 g of estradiol).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lastly, Evamist is a topical skin spray that delivers 1.53 mg with each spray [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H533430870\">",
"    <span class=\"h4\">",
"     Risk to children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The topical estrogen spray preparation, Evamist, has been associated with adverse effects in children and pets who were exposed to the drug via skin contact [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/20\">",
"     20",
"    </a>",
"    ]. The drug is sprayed on the skin between the elbow and wrist, on the inside of the forearm. Eight cases of unintended exposure have been reported in children ages three to five years. Adverse events have included nipple swelling and breast development in girls, and breast enlargement in boys, occurring weeks to months after the drug was initiated in the adult. In some cases, the effects were reversible after the estrogen spray was discontinued.",
"   </p>",
"   <p>",
"    Adverse events in pets exposed to Evamist",
"    <span class=\"nowrap\">",
"     (mammary/nipple",
"    </span>",
"    enlargement and vulvar swelling) have also been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H352147104\">",
"    <span class=\"h3\">",
"     Vaginal ring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal estrogen is most commonly used in very low doses for the management of vaginal atrophy. However, high doses of vaginal estrogen can also be used to treat vasomotor symptoms, much like a transdermal preparation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/21\">",
"     21",
"    </a>",
"    ]. As an example, a vaginal ring (Femring) is available in two doses, releasing 50 or 100 mcg of estradiol per day. We do not recommend these high doses, ie, systemic estrogen doses, in women who need therapy for genitourinary symptoms only. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6954?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of vaginal atrophy\", section on 'Vaginal estrogen therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H352147478\">",
"    <span class=\"h3\">",
"     Dose equivalents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies of safety and efficacy of postmenopausal estrogen have used conjugated estrogen 0.625 mg. This is considered to be standard dose estrogen; low dose preparations in general contain one-half the standard dose. The doses of other estrogens that are equivalent to conjugated estrogens include (",
"    <a class=\"graphic graphic_table graphicRef78136 \" href=\"UTD.htm?18/49/19230\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      1 mg micronized 17-beta-estradiol",
"     </li>",
"     <li>",
"      50",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      transdermal 17-beta-estradiol",
"     </li>",
"     <li>",
"      1.25 mg piperazine estrone sulfate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <br/>",
"    Estradiol gels and sprays are available in different strengths and delivery systems (pump, foil packets). Dosing equivalents depend upon the individual preparation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H533431036\">",
"    <span class=\"h3\">",
"     Low-dose estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the health risks reported in the Women's Health Initiative (WHI) with standard doses of estrogen (conjugated equine estrogen 0.625 mg daily), lower doses of estrogen (0.3 mg of conjugated estrogen and 0.5 mg of estradiol) have been studied as a potential alternative. Some studies suggest that lower doses of estrogen are effective for hot flashes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=see_link\">",
"     \"Menopausal hot flashes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ultra-low doses of estrogen (transdermal estradiol 0.014 mg and oral micronized estradiol 0.25 mg) also appear to prevent bone loss [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/11,22\">",
"     11,22",
"    </a>",
"    ], and are effective for hot flashes in some women. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Transdermal estrogen'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17831?source=see_link&amp;anchor=H7#H7\">",
"     \"Postmenopausal hormone therapy in the prevention and treatment of osteoporosis\", section on 'Low-dose estrogen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H533431174\">",
"    <span class=\"h2\">",
"     Factors affecting estrogen metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several situations in which the metabolism of estrogen is altered and therefore a change in the dose may be needed. Increased metabolism may result in lower serum estrogen concentrations, while decreased metabolism can result in higher serum concentrations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The above dosing guidelines may need to be increased in women taking anticonvulsant drugs (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ), which increase the hepatic clearance of estrogens and other steroid hormones. However, there is no way to predict how much more estrogen or progestin is needed [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/23\">",
"       23",
"      </a>",
"      ]. In this situation, a non-estrogen alternative to treat menopausal symptoms may be useful.",
"     </li>",
"     <li>",
"      In women receiving T4 replacement therapy, the addition of oral estrogen therapy may increase T4 requirements. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link\">",
"       \"Treatment of hypothyroidism\"",
"      </a>",
"      .) Similarly, in women receiving replacement glucocorticoids, the addition of oral estrogen would be expected to increase that requirement, although no data document that need.",
"     </li>",
"     <li>",
"      Concurrent acute alcohol ingestion and oral estradiol has been found to cause a threefold rise in serum estradiol concentrations, apparently by slowing the metabolism of estradiol [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/24\">",
"       24",
"      </a>",
"      ]. While it would be difficult to alter the medication dose based upon these findings, women taking exogenous estrogen should be encouraged to limit alcohol intake.",
"     </li>",
"     <li>",
"      Women with end-stage renal disease have higher serum estradiol concentrations after a dose of estrogen than do normal women [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H533431292\">",
"    <span class=\"h2\">",
"     Vaginal estrogen for vaginal atrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal administration of estrogen is ideal for treatment of the genitourinary symptoms of estrogen deficiency, because exposure of other organs is minimal. Doses can be administered that induce full estrogenization of vaginal tissue but have only minimal systemic effects. The potency of vaginal conjugated estrogens on vaginal tissue is estimated to be four times greater than that of oral conjugated estrogens, and the potency on other tissues is one-fourth as great. Therefore, when the desired effect is control of vaginal dryness, stress incontinence, or frequent urinary tract infections (",
"    <a class=\"graphic graphic_figure graphicRef79118 \" href=\"UTD.htm?20/31/20989\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/26\">",
"     26",
"    </a>",
"    ], vaginal estrogen therapy is an excellent choice. Women are advised not to have intercourse immediately after vaginal estrogen administration, in order to reduce the risk of penile absorption of estrogen.",
"   </p>",
"   <p>",
"    Recommended doses and regimens of vaginal estrogen (including vaginal cream, tablet, and ring preparations) are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8039?source=see_link\">",
"     \"Clinical manifestations and diagnosis of vaginal atrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6954?source=see_link\">",
"     \"Treatment of vaginal atrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Phytoestrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phytoestrogens, nonsteroidal compounds that occur naturally in many plants, fruits, and vegetables, have both estrogenic and antiestrogenic properties. There are three main types of phytoestrogens: isoflavones, coumestans, and lignans. Two types of isoflavones, genistein and daidzein, are found in soybeans, chickpeas, and lentils, and are thought to be the most potent estrogens of the phytoestrogens (although they are less potent than estradiol). Lignans (eg, enterolactone and enterodiol) are found in flaxseed, lentils, grains, fruits, and vegetables.",
"   </p>",
"   <p>",
"    It has been suggested that the lower risk of heart disease among Asian compared with Western populations is due to the high consumption of soybean products [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/27\">",
"     27",
"    </a>",
"    ]. This observation has led to increasing interest in the potential use of phytoestrogens as an alternative to HT for postmenopausal women. In fact, a high percentage of women (including women with a history of breast cancer) use dietary soy products to help manage menopause symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/28\">",
"     28",
"    </a>",
"    ]. In addition, many women perceive that phytoestrogens, because they are \"natural,\" are safer than HT, although this has never been proven.",
"   </p>",
"   <p>",
"    Herbal therapies such as black cohosh are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=see_link\">",
"     \"Menopausal hot flashes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Vasomotor symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on phytoestrogens and relief of vasomotor symptoms are conflicting, but the majority of studies have not demonstrated benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=see_link\">",
"     \"Menopausal hot flashes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     General health",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of 74 studies of phytoestrogens in humans concluded that, while evidence for the potential health benefits of phytoestrogens is increasing, it is still insufficient to recommend them in place of traditional HT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, a subsequent randomized, controlled trial in 202 healthy postmenopausal women over age 60 years randomly assigned to isoflavones (52 mg genistein and 41 mg daidzein) or powdered cow's milk protein for one year reported no improvement in cognitive function, plasma lipids, bone mineral density, quality of life, or depression in the isoflavone versus the control group [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=see_link\">",
"     \"Lipid lowering with diet or dietary supplements\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Bone mineral density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on phytoestrogens and bone mineral density have been conflicting with some studies reporting a beneficial effect on markers of bone resorption and bone mineral density in postmenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/32,33\">",
"     32,33",
"    </a>",
"    ], while others have seen no effect [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link&amp;anchor=H28#H28\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Isoflavones'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Breast cancer risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it is thought that a soy-based diet consumed throughout life may be associated with a lower breast cancer risk, there are some significant safety concerns about the impact of phytoestrogens on breast cancer risk if started after menopause. In vitro and in vivo studies have demonstrated that some phytoestrogens have estrogenic properties (promote breast cancer cell growth) in a low-estrogen environment, and antiestrogenic properties in a high-estrogen environment. If true, use of phytoestrogens could increase, not decrease, breast cancer risk in postmenopausal women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link&amp;anchor=H9304760#H9304760\">",
"     \"Factors that modify breast cancer risk in women\", section on 'Soy/Phytoestrogens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Endometrial effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;While short-term use of phytoestrogen supplements does not appear to have endometrial effects [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/34\">",
"     34",
"    </a>",
"    ], the impact of long-term use on endometrial carcinoma risk is controversial. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link&amp;anchor=H3338292#H3338292\">",
"     \"Endometrial carcinoma: Epidemiology and risk factors\", section on 'Phytoestrogens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In summary, while phytoestrogens may have possible health benefits, they may also have significant risks. Further study is needed before recommending them as an alternative to HT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Bioidentical hormone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While many postmenopausal women are turning to \"natural\" or \"bioidentical\" hormone therapy because of safety concerns about conventional hormone preparations, there is no evidence that these products are either safe or effective [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/35\">",
"     35",
"    </a>",
"    ]. The \"bioidentical\" approach generally refers to the prescribing of individualized doses of steroid hormones (compounded as pills, gels, sublingual tablets, or suppositories). The quality of compounded products may be substandard in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/36\">",
"     36",
"    </a>",
"    ]. In one study, potencies ranged from 67.5 to 268 percent of the amount specified on the labeling [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hormones most commonly compounded are estradiol, estrone, estriol, progesterone, testosterone, and DHEA. Women typically are asked to submit saliva or blood samples to measure baseline hormone concentrations. Based upon the results, the prescriber selects the individual hormones and doses to be compounded. This approach is expensive, as many providers perform frequent biochemical monitoring. &ldquo;Bioidentical hormones&rdquo; are derived from soy and plant extracts and are modified to be structurally identical to endogenous hormones. This approach is no different from what is used for most approved and commercially available postmenopausal hormone preparations (with the exception of conjugated estrogens, which are derived from urine).",
"   </p>",
"   <p>",
"    Proponents of the bioidentical approach claim that these preparations are effective for menopausal symptoms, yet are safer and better tolerated than commercially available preparations. However, a systematic review of the literature concluded that, while some of these products may decrease hot flushes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/38\">",
"     38",
"    </a>",
"    ], there is no evidence that \"bioidentical\" hormones have any advantage over conventional hormone therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/39\">",
"     39",
"    </a>",
"    ]. In addition, their safety has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/39\">",
"     39",
"    </a>",
"    ]. One pharmacokinetic study reported highly variable patterns of absorption with a commonly used bioidentical combination estrogen preparation; serum estradiol and estrone concentrations were lower than expected when compared with a comparable dose of a commercially available transdermal estradiol preparation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/40\">",
"     40",
"    </a>",
"    ]. Endometrial cancer has been reported with the use of bioidentical hormone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The US Food and Drug Administration (FDA) has published consumer information warning consumers that many claims made about the safety and efficacy of compounded bioidentical hormone products are false and misleading, with no credible scientific evidence to support them [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/42\">",
"     42",
"    </a>",
"    ]. In a 2006 position statement that was reissued in 2009, the Endocrine Society stated that there is no scientific evidence to support the efficacy or safety or effectiveness of compounded bioidentical hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PROGESTIN PREPARATIONS",
"    </span>",
"   </p>",
"   <p>",
"    Endometrial hyperplasia and cancer can occur after as little as six months of unopposed estrogen therapy; as a result, a progestin should be added in women who have not had a hysterectomy. Women who have undergone hysterectomy should not receive a progestin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link&amp;anchor=H256690677#H256690677\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\", section on 'Endometrial hyperplasia and carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the overall risk-benefit profile in the WHI for unopposed CEE appeared more favorable than for combined CEE 0.625 mg with MPA 2.5 mg, use of lower than standard progestin doses, less frequent administration (eg, quarterly), alternate routes (progestin IUDs), or lower doses of estrogen without progestin may not reliably prevent endometrial hyperplasia and carcinoma. Thus, we cannot recommend the use of unopposed estrogen, or non-standard progestin regimens in women with an intact uterus. However, if an alternative progestin regimen is used, close endometrial surveillance should be performed pending additional data on non-standard regimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link&amp;anchor=H256690677#H256690677\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\", section on 'Endometrial hyperplasia and carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Available progestin preparations are reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Medroxyprogesterone acetate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly prescribed progestin is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (MPA), typically given in a cyclic regimen (5 to 10",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or continuous regimen (2.5",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    Most studies of the efficacy of progestins, including the WHI, have been performed with this compound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Natural progesterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Natural oral micronized progesterone (Prometrium) has gained attention since it appears to protect the endometrium, is associated with less vaginal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/44\">",
"     44",
"    </a>",
"    ], and has little impact upon serum lipids [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/45\">",
"     45",
"    </a>",
"    ]. The usual dose is 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    cyclically or 100 to 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    continuously [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]; 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 12 days is the most carefully studied dose [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/45\">",
"     45",
"    </a>",
"    ]. Although it has been less well studied than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    , it is a reasonable choice for women who cannot tolerate medroxyprogesterone.",
"   </p>",
"   <p>",
"    High doses of oral micronized progesterone (300 to 400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    as was used historically in the management of premenstrual syndrome) may cause drowsiness [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/46\">",
"     46",
"    </a>",
"    ]. However, these doses would not be recommended for HT. The possible impact of natural progesterone on breast cancer and coronary heart disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=see_link&amp;anchor=H4#H4\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\", section on 'Effects of progestins'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=see_link&amp;anchor=H150020565#H150020565\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\", section on 'Type of progestin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Small studies of intravaginal progesterone administration suggest that it might be a useful alternative for postmenopausal women taking estrogen who cannot tolerate oral progestins [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. However, further data are needed before recommending this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H352147373\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most postmenopausal women in the United States receive medroxyprogesterone, there are postmenopausal hormone preparations that contain progestins derived from testosterone (19-nortestestosterone), such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone acetate",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     Levonorgestrel",
"    </a>",
"    is used in an intrauterine device. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Intrauterine device'",
"    </a>",
"    below.) These progestins are more commonly used in oral contraceptive preparations; they are testosterone derivatives and therefore have some weak androgenic actions.",
"   </p>",
"   <p>",
"    Drospirenone (DRSP), a newer progestin, is derived from 17 alpha-spironolactone and has progestogenic, antiandrogenic, and antimineralocorticoid activity. The first formulations to contain DRSP were monophasic oral contraceptives containing 30 and 20 mcg of ethinyl estradiol and 3 mg of drospirenone (Yasmin and Yaz). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18522?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on 'New progestins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drospirenone-containing preparations are also available for postmenopausal hormone therapy. One preparation, containing estradiol (1 mg) and drospirenone (2 mg), has been commercially available in Europe. A second preparation containing 1 mg estradiol, but only 0.5 mg of drospirenone, is also now available [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a trial of 1142 postmenopausal women randomly assigned to receive oral estradiol alone (1",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or in combination with drospirenone 0.5, 1, 2, or 3",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 13 months, all of the combination estradiol-drospirenone regimens decreased the risk of endometrial hyperplasia when compared with unopposed estrogen [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/52\">",
"     52",
"    </a>",
"    ]. Hyperkalemia was not observed in any patient, and favorable changes in lipids were noted in all of the estradiol-drospirenone groups (decreases in serum total cholesterol, triglycerides, and LDL concentrations, and increases in serum HDL when compared with baseline).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Intrauterine device",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     Levonorgestrel",
"    </a>",
"    -releasing intrauterine systems (LNG-IUS) are contraceptive agents that have been used off-label for endometrial protection by some peri- and postmenopausal women taking estrogen [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/53\">",
"     53",
"    </a>",
"    ]. The strategy is to avoid the potential excess risk of cardiovascular disease and breast cancer associated with systemic progestins such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link&amp;anchor=H178089454#H178089454\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\", section on 'Cardiovascular effects'",
"    </a>",
"    .) LNG-IUS provides very high intrauterine but low systemic concentrations of levonorgestrel; almost all women develop a nonproliferative, atrophic endometrium. LNG-IUS is also an attractive option for perimenopausal women who either need contraception, are having heavy bleeding, or both.",
"   </p>",
"   <p>",
"    Two doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    -releasing IUDs are available: one contains 52 mg initially released at 20",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    (Mirena&reg;, or LNG-20), the other contains 13.5 mg initially released at 14",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    (Skyla&trade;, or LNG-14). The lower dose has been available in many countries, but was only approved in the US in 2013.",
"   </p>",
"   <p>",
"    Two meta-analyses of trials in women using LNG-20 combined with estrogen therapy reported that the IUD was as good [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/54\">",
"     54",
"    </a>",
"    ] or better [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/55\">",
"     55",
"    </a>",
"    ] than estrogen combined with systemic progestins for preventing endometrial hyperplasia. Data for LNG-14 are more limited, but in a study of 150 peri- and postmenopausal women using the LNG-14 in addition to transdermal estradiol, no cases of endometrial hyperplasia were seen [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/56\">",
"     56",
"    </a>",
"    ]. However, only 101 (67 percent) of the 150 women underwent endometrial biopsy. In a second study, among 102 women who used two consecutive systems (LNG-14 for the first three years after which LNG-20 was inserted), endometrial biopsies showed atrophy in all but two women; theirs showed weak proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/57\">",
"     57",
"    </a>",
"    ]. There were no cases of hyperplasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DOSES AND BLEEDING PATTERNS WITH ESTROGEN REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patterns of vaginal bleeding in women receiving estrogen therapy vary with the regimen used.",
"    <br/>",
"   </p>",
"   <p>",
"    <strong>",
"     Unopposed estrogen &ndash;",
"    </strong>",
"    Use of unopposed estrogen in women with an intact uterus is",
"    <strong>",
"     not",
"    </strong>",
"    recommended. However, in rare circumstances, when a patient cannot tolerate any form of progestin therapy, unopposed estrogen is used and the patient must be monitored closely.",
"   </p>",
"   <p>",
"    <br/>",
"    The risk of endometrial cancer is the same whether the estrogen is given continuously or cyclically (five to seven \"off\" days at the end of the calendar month) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/58\">",
"     58",
"    </a>",
"    ]. For this reason, because vasomotor symptoms may recur during the \"off\" period, and because discontinuation complicates the regimen, continuous therapy is preferred.",
"   </p>",
"   <p>",
"    In women with an intact uterus taking unopposed estrogen, most have amenorrhea. This should",
"    <strong>",
"     not",
"    </strong>",
"    provide reassurance that endometrial hyperplasia has not developed. In a prospective, randomized, one-year multicenter study of patterns of vaginal bleeding in 1724 postmenopausal women taking different estrogen or estrogen-progestin regimens, 75 percent of the cycles in the women taking estrogen alone were characterized by amenorrhea and 25 percent by irregular spotting or bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/59\">",
"     59",
"    </a>",
"    ]. Unfortunately, the bleeding pattern does not correlate with endometrial histology, meaning that women with amenorrhea can have endometrial hyperplasia on biopsy. Therefore, routine endometrial biopsies are essential, as outlined below. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Endometrial monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <strong>",
"     Cyclic combined regimens &ndash;",
"    </strong>",
"    For many years the most popular cyclic regimen for women with a uterus consisted of 0.625 mg of conjugated estrogens on days 1 to 25 of the calendar month plus 10 mg of medroxyprogesterone on days 16 to 25. Lower doses of medroxyprogesterone have been used to minimize its side effects. In addition, the progestin is now usually given for 12 to 14 days to maximize the protective effect on the endometrium [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/60\">",
"     60",
"    </a>",
"    ]. More recently, natural micronized progesterone has become a popular alternative. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Natural progesterone'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Because, as noted above, there is no reason to stop the estrogen at the end of the month, a more typical cyclic regimen is daily estrogen (continuously) with 5 mg medroxyprogesterone (or 200 mg natural progesterone) on days 1 to 13 or 14 of each month.",
"   </p>",
"   <p>",
"    Eighty to 90 percent of women receiving cyclic combined hormone regimens have monthly withdrawal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Although the bleeding is often light, any menstrual bleeding is bothersome for most postmenopausal women, and it is a very important reason for discontinuation of therapy. In the majority of women the bleeding occurs after the last dose of progestin, but up to 25 percent have it while still taking the progestin [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/60\">",
"     60",
"    </a>",
"    ]. Most women eventually receive continuous combined regimens to avoid menstrual bleeding.",
"   </p>",
"   <p>",
"    <strong>",
"     Continuous combined regimens &ndash;",
"    </strong>",
"    Unlike cyclic therapy, continuous estrogen-progestin therapy (both hormones given every day) induces amenorrhea in most women (daily progestin eventually results in an atrophic endometrium). Estrogen and progestin can be administered separately. There are also a number of continuous combined preparations (both estrogen and progestin in one pill). If standard dose estrogen is used, recommended progestin doses would be medroxyprogesterone 2.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and natural progesterone 100",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    There are many studies demonstrating that continuous combined regimens are protective against endometrial hyperplasia and cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/46,61,62\">",
"     46,61,62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/34/40486?source=see_link\">",
"     \"Continuous postmenopausal hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the goal of continuous estrogen-progestin therapy is to induce amenorrhea, the main drawback has been irregular bleeding soon after therapy is started, which can persist for many months, even though most women eventually develop amenorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/63\">",
"     63",
"    </a>",
"    ]. Data from the Menopause Study Group demonstrated that the prevalence of bleeding is related to the number of years since menopause [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/59\">",
"     59",
"    </a>",
"    ]. Those women who were more than three years postmenopausal were less likely to have any bleeding during the first year of continuous therapy, as compared with women who were less than two years postmenopausal (78 versus 65 percent); the former are more likely to have endometrial atrophy when therapy is begun.",
"   </p>",
"   <p>",
"    One may start with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    as the progestin, particularly if cost is an issue. Micronized progesterone may, however, have advantages in selected women, as it has less effect of serum lipids. In addition, although data are limited, natural progesterone may have less of an effect on breast cancer risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=see_link&amp;anchor=H4#H4\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\", section on 'Effects of progestins'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=see_link&amp;anchor=H150020565#H150020565\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\", section on 'Type of progestin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     Quarterly progestin &ndash;",
"    </strong>",
"    Administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    for 14 days every three months has been investigated as a strategy for women who have difficulty tolerating progestin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. However, quarterly regimens may be associated with higher than normal rates of endometrial hyperplasia and, therefore, these regimens are not routinely recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/66\">",
"     66",
"    </a>",
"    ]. However, with increasing concerns about the role of progestin exposure on the risk of breast cancer, there is renewed interest in these types of regimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link&amp;anchor=H256690677#H256690677\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\", section on 'Endometrial hyperplasia and carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Endometrial monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal bleeding in women receiving estrogen therapy may require an evaluation of the endometrium to rule out hyperplasia. The indications for monitoring and the choice of test are dependent upon the estrogen regimen used.",
"   </p>",
"   <p>",
"    We recommend against the use of unopposed estrogen in women with an intact uterus because of the high risk of endometrial hyperplasia and endometrial cancer. For those women who choose this approach, baseline and annual endometrial monitoring are mandatory [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/67\">",
"     67",
"    </a>",
"    ]. In addition, any vaginal bleeding is an indication for endometrial monitoring.",
"   </p>",
"   <p>",
"    For women who are considering this route because they cannot tolerate oral progestin therapy, we strongly encourage them to try a progestin IUD before considering unopposed estrogen.",
"   </p>",
"   <p>",
"    As previously mentioned, transient bleeding is common and can be followed for the first six months with these regimens (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/34/40486?source=see_link\">",
"     \"Continuous postmenopausal hormone therapy\"",
"    </a>",
"    ). We suggest the following approach to endometrial monitoring:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In women with irregular bleeding, a pretreatment biopsy to rule out atypical endometrial hyperplasia or carcinoma should be performed.",
"     </li>",
"     <li>",
"      Vaginal bleeding can be followed for the first six months after beginning continuous combined therapy. Endometrial monitoring is necessary if the bleeding persists beyond this point.",
"     </li>",
"     <li>",
"      Women who have uterine bleeding after a period of amenorrhea should have endometrial monitoring, due to the relatively increased incidence of intrauterine pathology (eg, hyperplasia, carcinoma, fibroids, polyps). Monitoring should also be performed in women with bleeding that is refractory to hormonal manipulation (such as an increase in progestin dose).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     ANDROGEN THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The known decrease in ovarian androgen production rates and circulating androgen levels has caused concern that menopause might be associated with a decline in libido. An age-associated decline in sexual desire has been observed in both men and women. However, it is unclear whether the decline in libido in women is age- or menopause-related, since studies in women have not shown a significant correlation between libido and the serum estradiol or testosterone concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/68\">",
"     68",
"    </a>",
"    ]. Androgen production, sexual function, and the role of androgen therapy after menopause are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/45/20184?source=see_link\">",
"     \"Androgen production and therapy in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25258?source=see_link&amp;anchor=H8#H8\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\", section on 'Age and menopause'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H533432775\">",
"    <span class=\"h1\">",
"     TIBOLONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tibolone, a drug that has been widely used in Europe and other countries for nearly 20 years (but is not available in the US), is a synthetic steroid whose metabolites have estrogenic, androgenic, and progestogenic properties. It reduces vasomotor symptoms when compared with placebo, and has a beneficial effect on bone mineral density. Limited data suggest that it may also have a modest effect for symptoms of sexual dysfunction. However, tibolone has been associated with an increased risk of stroke and, therefore, we do not recommend its routine use for management of menopausal symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Tibolone'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=see_link\">",
"     \"Menopausal hot flashes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=see_link&amp;anchor=H27#H27\">",
"     \"Sexual dysfunction in women: Management\", section on 'Tibolone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data on the potential adverse effects of tibolone include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The LIFT trial (Long-term Intervention on Fracture with Tibolone), which was designed to determine the effect of tibolone on the risk of vertebral fracture in postmenopausal women (n = 4538, average 68 years), was stopped early because of an excess risk of stroke in women receiving tibolone when compared with placebo (relative risk 2.2) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/69\">",
"       69",
"      </a>",
"      ]. However, there were no significant differences in the risk of coronary heart disease or venous thromboembolism between the two groups.",
"     </li>",
"     <li>",
"      The Osteoporosis Prevention and Arterial effects of Tibolone (OPAL) trial in postmenopausal women reported that tibolone (2.5 mg) and conjugated estrogen-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      were both associated with progression of carotid intima-media thickness when compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/70\">",
"       70",
"      </a>",
"      ]. However, this interpretation is questionable, due to unexplained differences in the results for European and American women in the trial (which were then pooled for analysis).",
"     </li>",
"     <li>",
"      Small trials have reported a reduction in serum HDL concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/71,72\">",
"       71,72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other effects of tibolone:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although tibolone does not appear to increase mammographic density or the frequency of abnormal mammograms requiring follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/73\">",
"       73",
"      </a>",
"      ], data on breast cancer are conflicting [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/74-77\">",
"       74-77",
"      </a>",
"      ]. The Million Women Study reported an increased risk of breast cancer in current users of tibolone (RR 1.45, 95% CI 1.25-1.68) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/74\">",
"       74",
"      </a>",
"      ]. In contrast, in the LIFT trial described above [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/69\">",
"       69",
"      </a>",
"      ], a decreased risk of breast cancer was seen in the tibolone group compared with the placebo group (relative risk 0.32).",
"     </li>",
"     <li>",
"      In women with a personal history of breast cancer, tibolone may increase the risk of recurrence. This was illustrated in the LIBERATE trial (Livial Intervention following Breast Cancer; Efficacy, Recurrence, and Tolerability Endpoints), which was designed to compare the efficacy and safety of tibolone versus placebo for vasomotor symptoms in 3148 breast cancer survivors who were randomly assigned to receive tibolone 2.5 mg or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/78\">",
"       78",
"      </a>",
"      ]. After a mean follow-up of three years, 237 of 1556 women on tibolone (15 percent) had a breast cancer recurrence, compared with 138 of 1213 (11.4 percent) in the placebo group (HR 1.40, 95% CI 1.16-1.79). Vasomotor symptoms and bone mineral density improved with tibolone compared with placebo. Based upon these data, the use of tibolone is contraindicated in women with a history of breast cancer.",
"     </li>",
"     <li>",
"      Vaginal bleeding is fairly common in early postmenopausal women taking tibolone [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/71,79\">",
"       71,79",
"      </a>",
"      ]. In the LIFT trial, vaginal bleeding occurred in nearly 10 percent of women taking tibolone, significantly more than the 3 percent taking placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/69\">",
"       69",
"      </a>",
"      ]. However, tibolone has a better bleeding profile than combined continuous estrogen-progestin therapy; amenorrhea was reported more often in the tibolone group (71 to 78 percent) than in the hormone therapy group (45 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Observational data had suggested that tibolone was associated with an increased risk of endometrial hyperplasia when compared with combined estrogen-progestin therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/81\">",
"       81",
"      </a>",
"      ], but results from a randomized clinical trial of 3240 women did not confirm this [",
"      <a class=\"abstract\" href=\"UTD.htm?15/53/16218/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     NONHORMONAL ALTERNATIVES TO ESTROGEN THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all women are candidates for estrogen therapy for menopausal symptoms, and alternative therapies are available depending upon the indication for estrogen. These options are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=see_link&amp;anchor=H12#H12\">",
"     \"Menopausal hot flashes\", section on 'Other therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/27/40370?source=see_link\">",
"       \"Patient information: Menopause (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/59/26546?source=see_link\">",
"       \"Patient information: Menopause (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/4/32835?source=see_link\">",
"       \"Patient information: Postmenopausal hormone therapy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/16/32001?source=see_link\">",
"       \"Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H595401618\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once a decision has been made to treat a postmenopausal woman with estrogen, consideration should be given to the type of estrogen and the route by which it is to be given, as well as the need for progestin and the most appropriate progestin regimen. Estrogen is available in many forms: oral, transdermal, topical gels and lotions, intravaginal creams and tablets, and vaginal rings. In some countries, estrogen can also be given as a subcutaneous implant. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Estrogen preparations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hormone therapy should be prescribed at the lowest dose that will treat the bothersome symptom. The treatment interval should be long enough to cause symptom improvement, but should not extend indefinitely. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Estrogen preparations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic estrogen is indicated for the management of menopausal symptoms, most typically vasomotor flushes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=see_link\">",
"       \"Menopausal hot flashes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Based on observational studies, transdermal estradiol may be associated with a somewhat lower risk of DVT events than oral estradiol. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Systemic estrogen'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low dose vaginal estrogen should be considered for vaginal atrophy symptoms. (See",
"      <a class=\"local\" href=\"#H533431292\">",
"       'Vaginal estrogen for vaginal atrophy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/1\">",
"      Baker VL. Alternatives to oral estrogen replacement. Transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery. Obstet Gynecol Clin North Am 1994; 21:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/2\">",
"      Chetkowski RJ, Meldrum DR, Steingold KA, et al. Biologic effects of transdermal estradiol. N Engl J Med 1986; 314:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/3\">",
"      Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/4\">",
"      Van Erpecum KJ, Van Berge Henegouwen GP, Verschoor L, et al. Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women. Gastroenterology 1991; 100:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/5\">",
"      Clisham PR, Cedars MI, Greendale G, et al. Long-term transdermal estradiol therapy: effects on endometrial histology and bleeding patterns. Obstet Gynecol 1992; 79:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/6\">",
"      Stevenson JC, Cust MP, Gangar KF, et al. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990; 336:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/7\">",
"      Place VA, Powers M, Darley PE, et al. A double-blind comparative study of Estraderm and Premarin in the amelioration of postmenopausal symptoms. Am J Obstet Gynecol 1985; 152:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/8\">",
"      Pang SC, Greendale GA, Cedars MI, et al. Long-term effects of transdermal estradiol with and without medroxyprogesterone acetate. Fertil Steril 1993; 59:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/9\">",
"      Jurgens RW Jr, Downey LJ, Abernethy WD, et al. A comparison of circulating hormone levels in postmenopausal women receiving hormone replacement therapy. Am J Obstet Gynecol 1992; 167:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/10\">",
"      Mashchak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 1982; 144:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/11\">",
"      Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004; 104:443.",
"     </a>",
"    </li>",
"    <li>",
"     Pharmaceutical Approvals Monthly June 2004; 9:18.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/13\">",
"      Archer DF, Furst K, Tipping D, et al. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. Obstet Gynecol 1999; 94:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/14\">",
"      Simon JA, ESTRASORB Study Group. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms. Menopause 2006; 13:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/15\">",
"      \"The Pink Sheet\". F-D-C Reports, Inc. 2004; Volume 66; February 16:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/16\">",
"      Archer DF, EstroGel Study Group. Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women. Menopause 2003; 10:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/17\">",
"      Hedrick RE, Ackerman RT, Koltun WD, et al. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women. Menopause 2009; 16:132.",
"     </a>",
"    </li>",
"    <li>",
"     The Medical Letter 2007; 49:69.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/19\">",
"      Buster JE, Koltun WD, Pascual ML, et al. Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008; 111:1343.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Evamist (estradiol transdermal spray): Drug Safety Communication - Unintended Exposure of Children and Pets to Topical Estrogen file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm220548.htm (Accessed on September 21, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/21\">",
"      Speroff L. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstet Gynecol 2003; 102:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/22\">",
"      Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA 2003; 290:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/23\">",
"      Mattson RH, Cramer JA, Darney PD, Naftolin F. Use of oral contraceptives by women with epilepsy. JAMA 1986; 256:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/24\">",
"      Ginsburg ES, Mello NK, Mendelson JH, et al. Effects of alcohol ingestion on estrogens in postmenopausal women. JAMA 1996; 276:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/25\">",
"      Ginsburg ES, Owen WF Jr, Greenberg LM, et al. Estrogen absorption and metabolism in postmenopausal women with end-stage renal disease. J Clin Endocrinol Metab 1996; 81:4414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/26\">",
"      Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993; 329:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/27\">",
"      Lissin LW, Cooke JP. Phytoestrogens and cardiovascular health. J Am Coll Cardiol 2000; 35:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/28\">",
"      Newton KM, Buist DS, Keenan NL, et al. Use of alternative therapies for menopause symptoms: results of a population-based survey. Obstet Gynecol 2002; 100:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/29\">",
"      Glazier MG, Bowman MA. A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy. Arch Intern Med 2001; 161:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/30\">",
"      Kreijkamp-Kaspers S, Kok L, Grobbee DE, et al. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. JAMA 2004; 292:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/31\">",
"      Kok L, Kreijkamp-Kaspers S, Grobbee DE, et al. A randomized, placebo-controlled trial on the effects of soy protein containing isoflavones on quality of life in postmenopausal women. Menopause 2005; 12:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/32\">",
"      Nikander E, Mets&auml;-Heikkil&auml; M, Ylikorkala O, Tiitinen A. Effects of phytoestrogens on bone turnover in postmenopausal women with a history of breast cancer. J Clin Endocrinol Metab 2004; 89:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/33\">",
"      Mei J, Yeung SS, Kung AW. High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but not premenopausal women. J Clin Endocrinol Metab 2001; 86:5217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/34\">",
"      Nikander E, Rutanen EM, Nieminen P, et al. Lack of effect of isoflavonoids on the vagina and endometrium in postmenopausal women. Fertil Steril 2005; 83:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/35\">",
"      Cirigliano M. Bioidentical hormone therapy: a review of the evidence. J Womens Health (Larchmt) 2007; 16:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/36\">",
"      Mahaguna V, McDermott JM, Zhang F, Ochoa F. Investigation of product quality between extemporaneously compounded progesterone vaginal suppositories and an approved progesterone vaginal gel. Drug Dev Ind Pharm 2004; 30:1069.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Bio-identicals: Sorting myths from facts file://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm049311.htm (Accessed on November 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/38\">",
"      Takahashi K, Manabe A, Okada M, et al. Efficacy and safety of oral estriol for managing postmenopausal symptoms. Maturitas 2000; 34:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/39\">",
"      Boothby LA, Doering PL, Kipersztok S. Bioidentical hormone therapy: a review. Menopause 2004; 11:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/40\">",
"      Sood R, Warndahl RA, Schroeder DR, et al. Bioidentical compounded hormones: A pharmacokinetic evaluation in a randomized clinical trial. Maturitas 2013; 74:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/41\">",
"      Eden JA, Hacker NF, Fortune M. Three cases of endometrial cancer associated with \"bioidentical\" hormone replacement therapy. Med J Aust 2007; 187:244.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Bio-Identicals: Sorting Myths from Facts file://www.fda.gov/forconsumers/consumerupdates/ucm049311.htm (Accessed on February 05, 2013).",
"    </li>",
"    <li>",
"     The Endocrine Society Re-Issues Position Statement on Bioidentical Hormones - February 5, 2009 file://www.endo-society.org/media/press/2008/SOCIETYRE-ISSUESPOSITIONSTATEMENTONBIOIDENTICALHORMONES.cfm (Accessed on March 19, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/44\">",
"      Lindenfeld EA, Langer RD. Bleeding patterns of the hormone replacement therapies in the postmenopausal estrogen and progestin interventions trial. Obstet Gynecol 2002; 100:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/45\">",
"      Gillet JY, Andre G, Faguer B, et al. Induction of amenorrhea during hormone replacement therapy: optimal micronized progesterone dose. A multicenter study. Maturitas 1994; 19:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/46\">",
"      Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995; 273:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/47\">",
"      Hargrove JT, Maxson WS, Wentz AC, Burnett LS. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol 1989; 73:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/48\">",
"      Moorjani S, Dupont A, Labrie F, et al. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women. J Clin Endocrinol Metab 1991; 73:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/49\">",
"      de Ziegler D, Ferriani R, Moraes LA, Bulletti C. Vaginal progesterone in menopause: Crinone 4% in cyclical and constant combined regimens. Hum Reprod 2000; 15 Suppl 1:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/50\">",
"      Cicinelli E, de Ziegler D, Galantino P, et al. Twice-weekly transdermal estradiol and vaginal progesterone as continuous combined hormone replacement therapy in postmenopausal women: a 1-year prospective study. Am J Obstet Gynecol 2002; 187:556.",
"     </a>",
"    </li>",
"    <li>",
"     The Medical Letter Feb 12, 2007; 49:15.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/52\">",
"      Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005; 12:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/53\">",
"      Varila E, Wahlstr&ouml;m T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001; 76:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/54\">",
"      Wan YL, Holland C. The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review. Climacteric 2011; 14:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/55\">",
"      Somboonporn W, Panna S, Temtanakitpaisan T, et al. Effects of the levonorgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis. Menopause 2011; 18:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/56\">",
"      Wildemeersch D, Janssens D, Schacht E, et al. Intrauterine levonorgestrel delivered by a frameless system, combined with systemic estrogen: acceptability and endometrial safety after 3 years of use in peri- and postmenopausal women. Gynecol Endocrinol 2005; 20:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/57\">",
"      Wildemeersch D, Pylyser K, De Wever N, et al. Endometrial safety after 5 years of continuous combined transdermal estrogen and intrauterine levonorgestrel delivery for postmenopausal hormone substitution. Maturitas 2007; 57:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/58\">",
"      Schiff I, Sela HK, Cramer D, et al. Endometrial hyperplasia in women on cyclic or continuous estrogen regimens. Fertil Steril 1982; 37:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/59\">",
"      Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol 1994; 83:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/60\">",
"      Whitehead MI, Townsend PT, Pryse-Davies J, et al. Effects of various types and dosages of progestogens on the postmenopausal endometrium. J Reprod Med 1982; 27:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/61\">",
"      Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/62\">",
"      Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am J Obstet Gynecol 1994; 170:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/63\">",
"      Udoff L, Langenberg P, Adashi EY. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol 1995; 86:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/64\">",
"      Ettinger B, Selby J, Citron JT, et al. Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 1994; 83:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/65\">",
"      Hirvonen E, Salmi T, Puolakka J, et al. Can progestin be limited to every third month only in postmenopausal women taking estrogen? Maturitas 1995; 21:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/66\">",
"      Cerin A, Heldaas K, Moeller B. Adverse endometrial effects of long-cycle estrogen and progestogen replacement therapy. The Scandinavian LongCycle Study Group. N Engl J Med 1996; 334:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/67\">",
"      Greendale GA, Lee NP, Arriola ER. The menopause. Lancet 1999; 353:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/68\">",
"      Myers LS, Dixen J, Morrissette D, et al. Effects of estrogen, androgen, and progestin on sexual psychophysiology and behavior in postmenopausal women. J Clin Endocrinol Metab 1990; 70:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/69\">",
"      Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008; 359:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/70\">",
"      Bots ML, Evans GW, Riley W, et al. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. Eur Heart J 2006; 27:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/71\">",
"      Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 2002; 87:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/72\">",
"      Bjarnason NH, Bjarnason K, Haarbo J, et al. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab 1997; 82:1752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/73\">",
"      Banks E, Reeves G, Beral V, et al. Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect. Breast Cancer Res 2006; 8:R8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/74\">",
"      Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/75\">",
"      Lundstr&ouml;m E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002; 186:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/76\">",
"      Christodoulakos GE, Lambrinoudaki IV, Vourtsi AD, et al. Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study. Menopause 2002; 9:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/77\">",
"      Bruce D, Robinson J, McWilliams S, et al. Long-term effects of tibolone on mammographic density. Fertil Steril 2004; 82:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/78\">",
"      Kenemans P, Bundred NJ, Foidart JM, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009; 10:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/79\">",
"      Berning B, van Kuijk C, Bennink HJ, Fauser BC. Absent correlation between vaginal bleeding and oestradiol levels or endometrial morphology during tibolone use in early postmenopausal women. Maturitas 2000; 35:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/80\">",
"      Archer DF, Hendrix S, Gallagher JC, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab 2007; 92:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/53/16218/abstract/81\">",
"      Beral V, Bull D, Reeves G, Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005; 365:1543.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7446 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-9CA6F9C4F1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_53_16218=[""].join("\n");
var outline_f15_53_16218=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H595401618\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ESTROGEN PREPARATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Systemic estrogen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Oral estrogen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Transdermal estrogen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H533430863\">",
"      - Topical estradiol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H533430870\">",
"      Risk to children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H352147104\">",
"      - Vaginal ring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H352147478\">",
"      - Dose equivalents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H533431036\">",
"      - Low-dose estrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H533431174\">",
"      Factors affecting estrogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H533431292\">",
"      Vaginal estrogen for vaginal atrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Phytoestrogens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Vasomotor symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - General health",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Bone mineral density",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Breast cancer risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Endometrial effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Bioidentical hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PROGESTIN PREPARATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Medroxyprogesterone acetate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Natural progesterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H352147373\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Intrauterine device",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DOSES AND BLEEDING PATTERNS WITH ESTROGEN REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Endometrial monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      ANDROGEN THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H533432775\">",
"      TIBOLONE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      NONHORMONAL ALTERNATIVES TO ESTROGEN THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H595401618\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7446\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7446|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/11/39101\" title=\"figure 1\">",
"      Transdermal versus oral ERT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/31/20989\" title=\"figure 2\">",
"      ERT minimizes recurrent UTI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7446|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/49/19230\" title=\"table 1\">",
"      Estrogen products",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/45/20184?source=related_link\">",
"      Androgen production and therapy in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8039?source=related_link\">",
"      Clinical manifestations and diagnosis of vaginal atrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/34/40486?source=related_link\">",
"      Continuous postmenopausal hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=related_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=related_link\">",
"      Lipid lowering with diet or dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=related_link\">",
"      Menopausal hot flashes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18522?source=related_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/59/26546?source=related_link\">",
"      Patient information: Menopause (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/27/40370?source=related_link\">",
"      Patient information: Menopause (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/16/32001?source=related_link\">",
"      Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/4/32835?source=related_link\">",
"      Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=related_link\">",
"      Postmenopausal hormone therapy and the risk of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17831?source=related_link\">",
"      Postmenopausal hormone therapy in the prevention and treatment of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25258?source=related_link\">",
"      Sexual dysfunction in women: Epidemiology, risk factors, and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34985?source=related_link\">",
"      Sexual dysfunction in women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=related_link\">",
"      Treatment of menopausal symptoms with hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/50/6954?source=related_link\">",
"      Treatment of vaginal atrophy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_53_16219="Interventions based on stage";
var content_f15_53_16219=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Effective physician lifestyle interventions based upon patient's stage of change",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Precontemplation stage",
"       </td>",
"       <td>",
"        Provide background information on medical and personal reasons for change.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Contemplation stage",
"       </td>",
"       <td>",
"        Support patient's own motivation to make change; develop greater awareness of personal benefits to patient.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Preparation stage",
"       </td>",
"       <td>",
"        Assist in dealing with issues and barriers; collaborate on developing a specific plan.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Action stage",
"       </td>",
"       <td>",
"        Follow through with the plan; deal with issues related to",
"adherence to the initiation of change (issues may be present for weeks or months).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Maintenance stage",
"       </td>",
"       <td>",
"        Continue to emphasize long-term medical benefits and",
"personal motivation; deal with relapses as \"normal\" (reassess patient's",
"Stage of Change and continue to work with patient on change issues).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_53_16219=[""].join("\n");
var outline_f15_53_16219=null;
var title_f15_53_16220="Disseminated histo rx recs";
var content_f15_53_16220=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57457&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment recommendations for disseminated histoplasmosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Manifestation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Progressive disseminated histophasmosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Moderately severe to severe",
"       </td>",
"       <td>",
"        Liposomal AmB* (3.0 mg/kg daily), AmB lipid complex* (5.0 mg/kg daily), or AmB deoxycholate* (0.7 to 1.0 mg/kg daily) for 1 to 2 weeks, followed by itraconazole&bull; (200 mg twice daily for at least 12 months)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mild to moderate",
"       </td>",
"       <td>",
"        Itraconazole (200 mg twice daily for at least 12 months)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CNS histoplasmosis",
"       </td>",
"       <td>",
"        Liposomal AmB* (5.0 mg/kg daily for 4 to 6 weeks), followed by itraconazole&bull; (200 mg 2 to 3 times daily for at least 12 months)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    With regard to pregnancy, all azoles are contraindicated because of the risk of teratogenicity. Otherwise, the indications for treatment are not different in pregnancy, and lipid formulations of AmB are preferred. AmB deoxycholate is preferred for use in children because it is effective, well tolerated, and less costly. The dosage of itraconazole for children is 5.0 to 10.0 mg/kg in 2 divided doses, not to exceed 400 mg daily.",
"    <div class=\"footnotes\">",
"     AmB: amphotericin B* Liposomal AmB (3.0 mg/kg daily) or AmB lipid complex (5.0 mg/kg daily) are recommended for 1 to 2 weeks, except in patients with meningitis, for whom the dosage of liposomal AmB is 5.0 mg/kg daily for 4 to 6 weeks. The deoxycholate formulation of AmB (0.7 to 1.0 mg/kg daily) is an alternative to a lipid formulation in patients who are at low risk for nephrotoxicity.",
"     <br>",
"      &bull; Itraconazole should be given as a loading dose of 200 mg 3 times daily for the first 3 days, followed by 200 mg twice daily thereafter. Itraconazole (200 mg once daily) may be sufficient in patients with less severe manifestations of histoplasmosis. If used for prophylaxis, a dosage of 200 mg daily is recommended. Concentrations of itraconazole in serum should be monitored in patients being treated for chronic pulmonary, disseminated, or CNS histoplasmosis; a random serum concentration &gt;1.0 &micro;g/mL should be sought. Drug monitoring is infrequently needed for patients receiving shorter courses of therapy for acute pulmonary histoplasmosis and its complications.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Wheat, LJ, Freifeld, AG, Kleiman, MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45:807. Copyright &copy;2007 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_53_16220=[""].join("\n");
var outline_f15_53_16220=null;
var title_f15_53_16221="Neuromuscular disease on PFT";
var content_f15_53_16221=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Impact of neuromuscular disease on pulmonary function",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 299px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_53_16221=[""].join("\n");
var outline_f15_53_16221=null;
var title_f15_53_16222="Merkel relative survival by extent of disease at diagnosis";
var content_f15_53_16222=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62228&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Merkel cell carcinoma relative survival by extent of disease at diagnosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 305px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relative survival for Merkel cell carcinoma by extent of disease at time of diagnosis. Percent relative survival was calculated for cases in the National Cancer Database using age- and sex-matched control data from the Centers for Disease Control and Prevention.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_53_16222=[""].join("\n");
var outline_f15_53_16222=null;
var title_f15_53_16223="Contents: Neurooncology";
var content_f15_53_16223=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/63/1022\">",
"       Neurology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Neurooncology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Neurooncology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Benign tumors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/60/24520\">",
"           Craniopharyngioma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/18/40232\">",
"           Vestibular schwannoma (acoustic neuroma)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Brain metastases",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/63/39927\">",
"           Management of brain metastases in melanoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/26/39335\">",
"           Management of vasogenic edema in patients with primary and metastatic brain tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/58/6057\">",
"           Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/16/18697\">",
"           Seizures in patients with primary and metastatic brain tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/13/217\">",
"           Systemic therapy for brain metastases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/35/44601\">",
"           Treatment of brain metastases in favorable prognosis patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/40/36486\">",
"           Treatment of brain metastases in poor prognosis patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Classification",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/17/36117\">",
"           Classification of gliomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/1/2071\">",
"           Diagnosis and classification of low-grade gliomas",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Complications of therapy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/22/37226\">",
"           Complications of cranial irradiation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/32/2566\">",
"           Complications of cranial stereotactic radiosurgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/34/38437\">",
"           Complications of peripheral nerve irradiation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/1/7190\">",
"           Complications of spinal cord irradiation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Epidemiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/59/2997\">",
"           Incidence of primary brain tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/42/8874\">",
"           Risk factors for brain tumors",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General issues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/39/30327\">",
"           Anticoagulant and antiplatelet therapy in patients with brain tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/43/41655\">",
"           Brain tumor headache",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/3/25657\">",
"           Clinical presentation and diagnosis of brain tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/26/39335\">",
"           Management of vasogenic edema in patients with primary and metastatic brain tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/16/18697\">",
"           Seizures in patients with primary and metastatic brain tumors",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Leptomeningeal disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/48/24329\">",
"           Clinical features and diagnosis of leptomeningeal metastases from solid tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/17/39194\">",
"           Secondary involvement of the central nervous system by non-Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/53/26458\">",
"           Treatment of leptomeningeal metastases (carcinomatous meningitis)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Paraneoplastic syndromes of the nervous system",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/2/42023\">",
"           Opsoclonus myoclonus ataxia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/0/40968\">",
"           Overview of paraneoplastic syndromes of the nervous system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/56/906\">",
"           Paraneoplastic and autoimmune encephalitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/22/26983\">",
"           Paraneoplastic cerebellar degeneration",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/27/37304\">",
"           Paraneoplastic syndromes affecting peripheral nerve and muscle",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/27/6583\">",
"           Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/4/7239\">",
"           Paraneoplastic visual syndromes",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pediatric tumors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/0/2058\">",
"           Epidemiology, treatment, and prognosis of medulloblastoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/23/41332\">",
"           Histopathology and molecular pathogenesis of medulloblastoma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Radiation therapy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/22/37226\">",
"           Complications of cranial irradiation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/32/2566\">",
"           Complications of cranial stereotactic radiosurgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/34/38437\">",
"           Complications of peripheral nerve irradiation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/1/7190\">",
"           Complications of spinal cord irradiation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/35/44601\">",
"           Treatment of brain metastases in favorable prognosis patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Specific tumors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/25/42391\">",
"           Adjuvant chemotherapy for malignant gliomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/38/4712\">",
"           Adjuvant radiation therapy for malignant gliomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/45/4821\">",
"           Assessment of disease status and surveillance after treatment in patients with brain tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/25/42389\">",
"           Atypical and malignant meningiomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/40/7815\">",
"           Chordoma and chondrosarcoma of the skull base",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/5/22618\">",
"           Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/4/44103\">",
"           Clinical features, pathology, and prognostic factors for oligodendroglial tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/60/35784\">",
"           Clinical manifestations and initial surgical approach to patients with malignant gliomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/15/15609\">",
"           Clinical presentation, diagnosis, and staging evaluation of neuroblastoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/60/24520\">",
"           Craniopharyngioma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/1/2071\">",
"           Diagnosis and classification of low-grade gliomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/50/1832\">",
"           Diffuse pontine glioma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/51/15161\">",
"           Ependymoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/15/14585\">",
"           Epidemiology, pathogenesis, and pathology of neuroblastoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/0/2058\">",
"           Epidemiology, treatment, and prognosis of medulloblastoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/13/19674\">",
"           Experimental treatment approaches for malignant gliomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/40/40585\">",
"           Focal brainstem glioma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/43/695\">",
"           Hemangioblastoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/23/41332\">",
"           Histopathology and molecular pathogenesis of medulloblastoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/1/28694\">",
"           Intradural nerve sheath tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/6/12391\">",
"           Li-Fraumeni syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/33/44568\">",
"           Management of low-grade glioma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/43/15029\">",
"           Management of malignant gliomas in elderly patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/30/36328\">",
"           Management of recurrent malignant gliomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/60/25540\">",
"           Meningioma: Clinical presentation and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/54/20328\">",
"           Meningioma: Epidemiology, risk factors, and pathology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/21/14678\">",
"           Molecular biology and pathogenesis of von Hippel-Lindau disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/14/20712\">",
"           Neurofibromatosis type 2",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/46/12008\">",
"           Olfactory neuroblastoma (esthesioneuroblastoma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/16/39176\">",
"           Optic pathway glioma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/38/14954\">",
"           Paraganglioma and pheochromocytoma: Management of malignant disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/13/21720\">",
"           Paragangliomas of the head and neck",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/53/14169\">",
"           Pathogenesis and biology of malignant gliomas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/25/30105\">",
"           Pediatric intracranial germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/20/16714\">",
"           Pineal gland masses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/30/17894\">",
"           Sacrococcygeal germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/63/7161\">",
"           Spinal cord tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/2/4133\">",
"           Systemic treatment of recurrent meningioma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/9/18586\">",
"           Treatment and prognosis of neuroblastoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/36/44616\">",
"           Treatment of benign (WHO grade I) meningioma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/24/11655\">",
"           Treatment of oligodendroglial tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/6/35946\">",
"           Uncommon brain tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/18/40232\">",
"           Vestibular schwannoma (acoustic neuroma)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-889822A5BA-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f15_53_16223=[""].join("\n");
var outline_f15_53_16223=null;
